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Abstract 
The Wolfram Syndrome (WS) is an autosomal recessive neurodegenerative disorder 
characterised by insulin-dependent diabetes mellitus (IDDM) and bilateral progressive 
optic atrophy. Manifestations in neural and neuroendocrine tissues generally arise, but 
are not a requirement for diagnosis. A novel gene was identified in 1998 on 
chromosome 4p16.1 (WFS1 or Wolframin) that contains loss-of-function mutations in 
a majority of Wolfram patients. This gene encodes for a putative hydrophobic 
transmembrane protein of 890aa and its predicted molecular weight is 100.29 kDa 
based on the amino acid sequence. This thesis was intended to study the localisation 
and function of this gene product in order to gain insight into its role in the 
pathogenesis of diabetes mellitus and neurodegeneration. 
In order to study the role of the Wolframin gene in diabetes, its mRNA expression was 
analysed during the development of diabetes in the Nonobese Diabetic (NOD) mouse 
model. This showed a decrease in Wolframin expression in the pancreas of NOD mice 
9 days after induction for diabetes, indicating a possible involvement of Wolframin in 
the survival of ß-cells. 
Fibroblast cells and blood samples from Wolfram patients were obtained and analysed 
for their mutations. One patient was compound heterozygotic for two separate 
mutations and one patient was homozygotic for a single insertion leading to an early 
stop codon. RT-PCR of these cells showed no significant difference in mRNA 
expression as compared to either fibroblasts from first-grade relatives or control cells. 
These cells were used in various functional assays. First of all, microarray analysis 
was used to identify genes that are affected when the Wolframin gene is non- 
functional. These results lead to the investigation of the role of Wolframin in 
senescence using the markers of growth rate and radiation. No difference was found 
between fibroblasts from a Wolfram patient and her sibling, not supporting a role for 
Wolframin in senescence. 
Since the mouse homologue is 83% identical to the human variant on an amino acid 
level it is likely that there is also functional homology. Therefore, in order to study the 
pathomechanisms acting in human disease, a knock-out mouse construct was produced 
thus overcoming the limitation to obtain human material. Two constructs were 
electroporated into embryonic stem cells and so far a total of 1080 colonies were 
screened, however, no positive clones were obtained. 
In order to investigate this gene on a protein level, antibodies were raised against the 
N- and C- terminus. The respective protein was found to be expressed in many tissues 
and cell lines with the highest expression in brain, pancreas, heart and insulinoma ß- 
cell lines. Using sub-cellular fractionation techniques, the protein was found 
exclusively in microsomal fractions. Immunofluorescence on transfected cos-7 cells 
showed intracellular localisation to the endoplasmic reticulum. Incubating mouse 
pancreas slices with the Wolframin antibody showed exclusive staining in the 0-cells 
and co-localisation to insulin. Immunofluorescence analysis also showed 
immunoreactivity to structures of the limbic system in the mouse brain. These results 
give the first clues towards a possible function in processing or trafficking of proteins 
involved in the survival of neuronal and endocrine cells. 
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Chanter 1. Introduction 
Diabetes mellitus is a common feature in over 40 different inherited syndromic 
diseases. Most of these diabetic syndromes are likely caused by a monogenetic defect. 
The genes responsible for these syndromes can be found on many different 
chromosomes and most are inherited in an autosomal recessive manner. These 
"diabetic syndromes" are characterised by diabetes accompanied by a variety of 
neurodegenerative symptoms, with deafness and optical abnormalities among the most 
common. Understanding the molecular mechanisms behind these syndromes is 
important to the understanding of the relationship between diabetes and the subsequent 
neurodegenerative symptoms found in these diseases. Some of the genes responsible 
for these syndromes are either located on mitochondrial DNA and therefore directly 
affect energy metabolism, or are located on nuclear DNA but affect mitochondrial 
functions by encoding for a mitochondrial-localised protein. 
Mitochondrial DNA (mtDNA) is important because it encodes 13 of the genes for 
oxidative phosphorylation (OXPHOS), which is important for energy production and 
cellular respiration (Chinnery, Howell et al. 1999). When OXPHOS is stimulated in 
the mitochondria, ATP is produced. An increase in ATP causes closure of the ATP- 
dependent potassium channels, which in turn results in an opening of calcium channels 
in pancreatic ß-cells. This increase in calcium levels triggers insulin secretion in 
insulin producing ß-cells. Mutations in mtDNA which affect OXPHOS proteins and 
subsequent ATP production could thus be one cause of diabetes mellitus by reducing 
insulin secretion (Gerbitz, Gempel et al. 1996). Two important syndromes in which 
the underlying genetic defect has been identified as being based on mitochondrial 
2 
functions are the maternally inherited diabetes-deafness syndrome, and Friedreich's 
ataxia. 
The diabetes-deafness syndrome is caused by a point mutation at mtDNA nucleotide 
pair 3243 (Reardon, Ross et al. 1992). The diabetes here is a mild form of adult onset 
type 2 diabetes thought to be due to ß-cell failure (Kadowaki, Kadowaki et al. 1994). 
In addition to being susceptible to diabetic retinopathy, many of these patients also 
have pigmentary retinal dystrophy (Smith, Bain et al. 1999). Diabetic retinopathy is a 
condition common to type 2 diabetics, where prolonged diabetes damages tiny blood 
vessels in the retina, which in turn causes bleeding and clouds vision. Pigmentary 
retinal dystrophy, on the other hand, is caused by pigmentary degeneration of the 
retina. 
FRDA1 (Friedreich's ataxia) is a mitochondrial disease where diabetes mellitus is 
present in 20 - 30% of all cases. Normal symptoms are cerebral ataxia, peripheral 
neuropathy and hypertrophic cardiomyopathy (OMIM 229300). Based on studies with 
the yeast homologue, Frataxin, the affected gene, appears to be involved in 
mitochondrial iron transport. Mutations in Frataxin cause iron accumulation, COX 
deficiency and mtDNA instability (Wong, Yang et al. 1999). 
A variety of other diseases have been described which are based on mitochondrial 
malfunctions where neurodegeneration plays a leading role. For instance, LHON 
(Leber Hereditary optic neuropathy) is characterised by bilateral optical atrophy and 
central vision loss and is caused by one or more of three single mtDNA mutations, 
where only one mutation is required for LHON (Wallace, Singh et al. 1988). Other 
missense mutations can be found at a higher frequency in LHON patients and can 
influence the severity of the symptoms. For example, a base exchange at nucleotide 
base pair 14459 (np14459) in the ND6 gene causes LHON in association with 
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Dystonia. This indicates a variability of symptoms associated with missense mutations 
(Lamminen, Huoponen et al. 1997). 
Leigh Syndrome (LS) is a severe neurodegenerative disorder characterised by 
dysfunction of the brain stem and basal ganglia (Leigh, 1951). Magnetic resonance 
imaging (MRI) of affected infants shows lesions in the brain stem, thalamus and 
posterior columns of the spinal cord (Manzi, Hager et al. 1990). LS is genetically 
heterogeneous and can be caused by mtDNA mutations, autosomal recessive defects of 
a nuclear gene and can even be inherited as an X-linked trait (OMIM: 208800,252011, 
220110,252010). In all cases, however, the terminal oxidative metabolism is affected. 
The neurodegeneration is therefore most likely caused by a failure of energy 
production in the developing brain (Filiano, Goldenthal et al. 2002). 
The Mohr-Tranebjaerg Syndrome (MTS) is an X-linked form of syndromic 
sensorineural deafness. Symptoms are: progressive sensorineural deafness, cortical 
blindness, dystonia and mental deterioration (Jin, 1996). The responsible gene in 
humans, DDP1 is a mitochondrial protein that resembles the small yeast Tim proteins, 
Tim9, Tim10 and Tim12, which are located in the intermitochondrial space and are 
responsible for the import of certain proteins into the mitochondrial inner membrane 
(Bauer, Rothbauer et al. 1999). Thus, it has been hypothesised that a defect in the 
import of mitochondrial proteins might cause this disease (Bauer, Rothbauer et al. 
1999). 
In a few cases, the responsible gene has no connection to mitochondrial function. For 
example, the gene responsible for Wolcott-Rallison syndrome, a disease distinguished 
by permanent neonatal diabetes (Wolcott and Rallison 1972), was found to be located 
on chromosome 2p12. This gene, EIF2AK3, encoding translation initiation factor 2-a 
kinase 3, regulates protein translation and is highly expressed in pancreatic islets 
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(Delepine, Nicolino et al. 2000). No individual with the Wolcott-Rallison syndrome 
has been reported to live beyond the teenage years. 
The thiamine-responsive megaloblastic anaemia syndrome is characterised by 
megaloblastic anaemia, childhood-onset non-autoimmune diabetes mellitus and 
sensorineural deafness. Some patients show abnormalities of the retina and optic 
nerve, including optic atrophy (Randall, Scheithauer et al. 1985; Rindi, Patrini et al. 
1994). A gene has been mapped to chromosome Ig23.3 that contains mutations in 
affected individuals (Diaz, Banikazemi et al. 1999; Fleming, Tartaglini et al. 1999; 
Labay, Raz et al. 1999). This gene is a vitamin transporter gene, SLC19A2 and 
encodes for a transmembrane protein, THTR-1. THTR-1 is thought to be a high- 
affinity thiamine transporter as these patients show reduced activity of thiamine- 
dependent enzymes (Fleming, Tartaglini et al. 1999). 
The analysis of such characterised diabetes related disorders provides a strong 
indication that the phenotype of diabetic patients with sensorineural deafness and 
unrelated neurological features is due to underlying mitochondrial defects. Another of 
these diabetic syndromes with similar symptoms in which the responsible gene has 
been recently identified is the so-called Wolfram syndrome. 
The Wolfram Syndrome (WS) was first described in 1938 by DJ Wolfram and HP 
Wagner, who observed four siblings out of eight presenting both diabetes mellitus and 
bilateral progressive primary optic atrophy (Wolfram and Wagener 1938). Non- 
autoimmune, juvenile onset diabetes mellitus and bilateral progressive optic atrophy 
are the two obligatory features of the Wolfram Syndrome, where diabetes mellitus 
normally occurs in the first decade and the latter occurs in the second decade of life. 
The acronym DIDMOAD arose after the discovery of additional clinical features and 
comprises the four most commonly seen: Diabetes Insipidus, Diabetes Mellitus, Optic 
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Atrophy and Deafness (Fraser and Gunn 1977; Richardson and Hamilton 1977). 
Wolfram syndrome is a progressive neurodegenerative disorder affecting the central 
and peripheral nervous systems as well as the neuroendocrine system. Predisposition 
to psychiatric illness such as depression and psychotic behaviour has also been 
associated with Wolfram syndrome patients (Evans, Lawson et al. 2000). Inheritance 
occurs in an autosomal recessive manner with approximately 25% of patients being 
consanguineous. The prevalence is very low at 1 in 100,000 in a US study and 1 in 
770,000 based on investigations in the UK (Barrett, Bundey et al. 1995; Kinsley, Swift 
et al. 1995). Accordingly, the carrier frequency could be calculated to be 1 in 175 to 
350 (Barrett, Bundey et al. 1995). 
1.1 Clinical features of the Wolfram syndrome 
1.1.1 Overview 
There are two major types of diabetes mellitus: the so-called type 1 and type 2 
diabetes. Type 1 diabetes or insulin dependent diabetes mellitus (IDDM) is normally 
juvenile onset and is due to an autoimmune response where autoantibodies attack 
insulin-producing ß-cells, thus resulting in drastically reduced insulin production 
(Soeldner and Slone 1965). Insulin is required for the uptake of glucose from the 
blood stream into the cell. Type 2 diabetes or non-insulin dependent diabetes mellitus 
(NIDDM) is usually late onset and generally preceded by insulin resistance (Bogardus, 
Lillioja et al. 1989; Warram, Martin et al. 1990; Martin, Warram et al. 1992). Obesity 
and nutrition have been shown to play a large role in the occurrence of this disorder. 
Unlike type 1 diabetics, type 2 diabetics do produce insulin, however the insulin 
cannot function properly to cause transport of glucose from the blood system into cells. 
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Type 1 diabetics need to regulate their glucose early on with insulin injections. In later 
stages of type 2 diabetes, insulin production exhausts and finally also many of these 
patients need to be treated with insulin. 
The diabetes in WS usually begins within the 1$` decade of life and rapidly becomes 
insulin-dependent (Barrett and Bundey 1997). In contrast to type 1 diabetes, the 
diabetes in Wolfram syndrome is non-autoimmune. In particular, autoantibodies 
against islet cells and GAD65, an enzyme that catalyzes the synthesis of y- 
aminobutyric acid in the ß-cell, are negative (Baekkeskov, Aanstoot et al. 1990). The 
HLA (human leukocyte antigen) class 2 molecule is responsible for the presentation of 
CD4+ T-cell antigens in the immune system and is the gene area most associated with 
type 1 diabetes. HLA -typing in WS patients revealed no significant difference to non- 
diabetic controls (Bertrams, Wendel et al. 1983; Monson and Boucher 1983). In 
comparison, 90% of type 1 diabetics carry specific histocompatibility haplotypes. The 
lack of autoimmune markers and selective absence of ß-cells suggest that the diabetes 
in WS is due to a genetically programmed selective loss of ß-cells and therefore a 
decrease in production of insulin (Karasik, O'Hara et al. 1989). 
The optic atrophy is a bilateral degeneration of the optic nerve and usually manifests 
after onset of diabetes (Barrett, Bundey et al. 1997). It presents with reduced colour 
vision and visual acuity leading to blindness in most of the patients. Abnormal retinal 
pigmentation is usually absent. Visual evoked potentials showed abnormalities, which 
are typical for optic nerve disease. Therefore, loss of vision in these patients is not a 
result of diabetic retinopathy (Barrett, Bundey et at. 1997), a condition that can arise 
after prolonged diabetes. 
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Diabetes insipidus is caused by a malfunction of or lack of the antidiuretic hormone, 
vasopressin (VP). Vasopressin is made by the cells of the hypothalamus and is stored 
and secreted by the posterior pituitary gland. This hormone gets released into the 
bloodstream where it causes tubules within the kidney to reabsorb water and thus 
concentrates urine. Therefore, such patients must urinate frequently and replenish with 
plenty of fluids. The diabetes insipidus in DIDMOAD is cranial and can be partial or 
complete (Peden, Gay et al. 1986). It begins at the hypothalamo-pituitary level and 
can be sufficiently treated by nasal application of an antidiuretic hormone and is 
therefore non-nephrogenic in origin (Thompson, Charlton et al. 1989). 
Immunostaining shows no reactivity for processed vasopressin in the supraoptic and 
paraventricular nuclei of WS patients, although the precursor is present. This suggests 
a possible defect in VP precursor processing (Gabreels, Swaab et al. 1998). 
The deafness in WS results from a progressive sensorineural hearing loss on both sides 
affecting the high frequencies (Young, Ives et al. 2001). Often hearing aids are 
required. Such hearing loss is relatively common in the general population and is 
based on a diverse genetic background. DIDMOAD patients show a loss of nerve 
fibres in the cochlear nerves and mild gliosis in the auditory brainstem (Genis, Davalos 
et al. 1997). 
Additional, but less frequent features are caused by disturbances of the neuroendocrine 
system and by renal tract and neurological abnormalities. The irregularities of the 
urinary tract include: bladder atony, incontinence and recurrent infections and are 
based on a dilated renal outflow tract, likely due to degeneration of the nerves leading 
to the ureters and urinary bladder (Chu, Staff et al. 1986). 
The most common neurological features are; ataxia, nystagmus, peripheral neuropathy 
and depression (Barrett, Bundey et al. 1995). Pituitary-gonadal malfunctions such as: 
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hypogonadism, menstrual irregularities and sexual retardation are less common and 
normal pregnancy in patients and partners of patients is possible (Peden, Gay et al. 
1986). 
1.1.2 Prevalence of the various clinical features and their age of onset 
Diabetes mellitus usually manifests itself as the first symptom before the age of ten. It 
is followed by optic atrophy, which occurs at a median age of around 11 years (Barrett, 
Bundey et al. 1997). All additional features, however, develop later during the course 
of the disease. In particular, diabetes insipidus and deafness usually appear in the 
second decade, the renal tract abnormalities early in the third decade and neurological 
complications develop late with a median onset in the fourth decade (Barrett and 
Bundey 1997). The prevalence of the additional features range between 50% and 75%. 
However, in the individual patient, the obligatory symptoms are associated with a 
variable spectrum of additional features. 
In general, Wolfram syndrome leads to a premature death at a median age of 30 (25- 
40) years (Barrett, Bundey et at. 1995). Central respiratory failure is presumably due 
to brain-stem atrophy and commonly causes premature death in these patients (Barrett 
and Bundey 1997). 
1.2 Brain atrophy 
In general, the neurological symptoms found in WS reflect local degeneration and 
atrophies of distinct brain regions. This can best be seen in an example of magnetic 
resonance imaging in comparison to a normal control (Rando, Horton et al. 1992; Saiz, 
Vila et at. 1995; Galluzzi, Filosomi et al. 1999). Figure 1.1 shows one such example. 
The abnormalities that can be seen include: brain atrophy of the cerebral cortex and 
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brain stem and severe atrophy of the cerebellum. In addition, atrophies of the pons and 
medulla can be seen which might cause respiratory failure, thereby determining the 
fate of many of these patients. Atrophy of the hypothalamus, the region that produces 
vasopressin, can also be seen. In some cases, specific alteration of the pituitary gland 
and reduced signals or shrinkage of the optic nerve can be seen (Galluzzi, Filosomi et 
al. 1999). 
Figure 1.1 MRI of a control person and a Wolfram patient. In the patient sample, a generalized brain 
atrophy, pronounced atrophy of the cerebellum (arrow) and atrophy of the brain stem (arrow head) can 
be seen. Also of note are an absence or reduced signal in structures of the limbic system. 
1.3 The Wolfram Disease Gene 
1.3.1 Linkage analysis 
Although Wolfram patients have been characterised extensively on a clinical level, the 
defective gene and the underlying pathomechanism of this disorder are only beginning 
to be unravelled. In 1994, the Wolfram disease gene was mapped using microsatellite 
repeat polymorphisms reported in the Genethon map of the human genome 
Control Wolfram syndrome Patient 
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(Polymeropoulos, Swift et al. 1994). Based on a linkage analysis of 11 families, the 
gene was found to be linked to markers on the short arm of chromosome 4. The 
location of the gene was refined in 1996 to the interval between D4S432 and D4S431 
by the lab of Sarah Bundey. This provided the first piece of evidence that WS was not 
a mitochondrial DNA disease (Collier, Barrett et al. 1996). 
Assuming that the disease locus was linked to this interval, Strom et al. (1998) 
screened for single recombination events in DNA from available Wolfram families. 
This led to a further refined critical interval between D4S431 and D4S2354 (Strom, 
Hortnagel et al. 1998). This region was sequenced and available early during the 
Human Genome Project. Both Strom et al. (1998) and Inoue et al. (1998) analysed the 
DNA sequences falling into the critical interval at 4p16.1. 
Only five genes were predicted within this region by screening expressed sequence 
tags (EST's) and using exon prediction programs (Inoue, Tanizawa et al. 1998; Strom, 
Hortnagel et al. 1998). Two of them were already known genes: DRP-1 the gene for 
di-hydro-pyrminidase-related protein-1 and BRg, a gene for a putative subunit of a 
human protein phosphatase. WM1 and WM3 were novel authentic genes, partially 
covered by EST's. WM4 appeared not to be a true gene since no expressed sequences 
could be found in EST databases. Thus, the candidate genes for Wolfram syndrome 
were: WM1, WM3, DRP-1 and BRg. 
Based on this information, mutational analysis of all four genes in various patients was 
performed. All exons from these four genes were amplified and screened by single- 
strand conformation polymorphism (SSCP) analysis. For SSCP analysis, DNA 
fragments were amplified and subjected to non-denaturing polyacrylamide gel 
electrophoresis. Since single stranded nucleic acids form secondary structures in 
solution that can be altered by only a single nucleotide substitution, mutations in the 
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DNA can be seen as a mobility shift. Polymorphic fragments where mobility gel shifts 
were seen were directly sequenced from the PCR product. Sequencing revealed 
mutations in only the WM1 gene in a majority of the cases tested (Inoue, Tanizawa et 
al. 1998; Strom, Hortnagel et al. 1998). The lack of mutations in WMI in some of 
these patients could be accounted for by the fact that intron-exon boundaries and the 
non-coding exon 1 were not included in this analysis. Also, due to its high phenotypic 
heterogeneity, it could be possible that another locus plays a role in this disorder. 
WMI is a 33.4 kb spanning region consisting of 8 exons (Inoue, Tanizawa et al. 1998). 
The coding region includes exons 2 to 8, where exon 8 encodes more than 50% of the 
entire protein. The structure of WMI can be seen in Figure 1.2. This gene was named 
Wolframin by Strom et al. and WFSI by Inoue and co-workers. Since Strom et al. is a 
collaborating group here at the Institute for Diabetes Research, their nomenclature will 
consistently be used in this thesis. 
Exon 
- 33.4 kb 
DRP-1 WM4 WM3 BR 
3' 5' 3' 5' 3 5' 353 5' 
Strom et al. Human Molecular Genetics (1998) 
Figure 1.2 Structure of the Wolframin gene. The coding region contains 8 exons, indicated here with 
boxes. The last exon, exon 8, is by far the largest. The total genomic sequence consists of 33.4 kb of 
information 
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1.3.2 Mutation Analysis 
The mutations found on the Wolframin gene included; nonsense, frameshift, missense, 
deletions and insertions (Strom, Hortnage) et al. 1998). Most patients are either 
homozygous for a single mutation on both alleles or compound heterozygous for two 
different mutations on two separate alleles. Therefore, loss-of-function mutations of 
the Wolframin gene are responsible for the phenotype found in DIDMOAD. Most of 
the causative mutations are located in exon 8 (Hardy, Khanim et al. 1999). This seems 
plausible considering the large size of this exon. 
60% of all individuals containing mutations on both Wolframin alleles were reported 
having psychiatric problems, 25% being severe enough to lead to hospitalisation or 
even suicide (Swift, Sadler et al. 1990). Molecular genotyping has shown that 
individuals carrying mutations on even a single Wolframin allele are at a 26-fold 
higher risk of being hospitalised for psychiatric problems than non-carriers (Swift and 
Swift 2000). The common Wolframin variant, A1a559Thr, which was absent in a 
majority of the controls tested, has been suggested to be a risk allele for bipolar and 
unipolar affective disorder (Furlong, Ho et al. 1999). Unipolar affective disorder is 
characterised by prolonged periods of depression. Bipolar affective disorder includes 
drastic mood swings from periods of depression followed by feelings of euphoria 
(Gershon 1990). 
Interestingly, it has recently been shown that single heterozygous mutations in 
Wolframin can cause autosomal dominant non-syndromic low frequency sensorineural 
hearing loss (LFSNHL) (Bespalova, Van Camp et al. 2001; Young, Ives et al. 2001). 
This means, certain mutations in the gene responsible for WS are able to cause a 
separate disease. Even though hearing loss is a frequent symptom of Wolfram 
patients, it is normally restricted to the high frequencies and not to the low frequencies 
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as in LFSNHL. This phenomenon is not completely understood, however, the 
progressive nature of LFSNHL suggests a role for Wolframin in sound transduction 
rather than in development of cochlear cells (Young, Ives et al. 2001). The mutations 
in LFSNHL have all been found in the portion of exon 8 that encodes for the C- 
terminal domain. No mutations have yet been found in the N-terminal or 
transmembrane domains, suggesting these mutations are dominant-negative by 
interfering with the specific function of the C-terminal domain (Bespalova, Van Camp 
et al. 2001). 
Family Patient Mutation Type Exon 
1 5519 1380de19* 9 bp deletion 8 
2 13775 460+1G>A* 5' splice signal 4 
4 13070 599delT* frameshift 5 
5 13885 Q366X, 1096C>T stop 8 
6 13062 Q226X, 676C>T stop 6 
Q819X, 2455C>T stop 8 
7 13076 599delT frameshift 5 
Y669C missense 8 
8 13073 Q366X, 1096C>T stop 8 
Q520X, 1558C>T stop 8 
9 13781 1523delAT* frameshift 8 
12 12131 2164ins24* 24 bp insertion 8 
13 2922 2647de14* frameshift 8 
W700X, 2099G>A stop 8 
14 2984 1918de110* frameshift 5 
15 15572 460+1G>A* 5' splice signal 6 
16 16077 461-1G>C* 3' splice signal 8 
17 2979 W371X, 1112G>A stop 8 
R629W, 1885C>T missense 8 
Strom et al. Human Molecular Genetics (1998) 
Inoue et al. Nature Genetics (1998) 
Figure 1.3 Screening results of two independent experiments. * indicates homozygous mutations. 
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Various groups have tried to analyse mutations in the Wolframin gene for correlation 
to phenotype. Hardy and co-workers screened 30 patients from 19 families for 
mutations in the coding region of the Wolframin gene. Results of this study and others 
show that a majority of the patients are compound heterozygotes for two mutations 
leading to loss-of-function of the gene. For example, 28 of Hardy's 30 patients contain 
mutations on both alleles. Since intron boundary regions were not tested, these could 
account for the missing mutations. Figure 1.3 summarises the screening results from 
three independent studies (Barrett, Bundey et al. 1995; Inoue, Tanizawa et al. 1998; 
Strom, Hortnagel et al. 1998). It turns out that direct loss-of-function mutations 
resulting in an altered stop codon are the predominant cause of the Wolfram syndrome. 
These comprise about 80% of the mutations, whereas missense mutations are present 
in only roughly 20% of all cases. Most mutations can be found in the last exon and 
47% of all mutations resulted in loss of the carboxy terminal tail, indicating that the 
carboxy terminus most likely plays an important role in protein function (Hardy, 
Khanim et al. 1999). In all additional patients studied so far, including the studies of 
Inoue and Hardy, no common mutations have been identified. No phenotype-genotype 
correlation has been observed based on the comparison of mutation location with 
severity of symptoms, clinical course or age of onset. 
1.3.3 Additional Locus 
Mutational analysis has provided evidence that the Wolframin gene contains loss-of- 
function mutations in a majority of patients. Although there is no indication that 
specific mutations cause certain phenotypes, the symptoms of this disease are so 
diverse that patients can be categorised into severity and prevalence of one symptom 
over another. For example, locus heterogeneity was suspected when a family with a 
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variable phenotype (optical atrophy presented one decade before diabetes mellitus) 
showed no linkage to Wolframin (Collier, Barrett et al. 1996). In another study, 16 
patients were investigated who showed no sign of having or obtaining diabetes 
insipidus (El-Shanti, Lidral et al. 2000). In these families, linkage was found to a 
second locus on 4q22-24 instead of on markers for 4p16. This region includes 22 
genes and needs to be narrowed down further by positional cloning. Genetic 
heterogeneity in DIDMOAD is not surprising considering the multitude of symptoms 
seen in these patients. In addition, the main symptom, diabetes mellitus, is correlated 
with mutations in many diverse genes and located in many different positions within 
the genome. In fact, type 1 diabetes itself is a result of many genes working together, 
where even environmental factors may play a large role (FÜchtenbusch 1995). 
1.4 Expressional analysis 
Northern blot analysis revealed that the Wolframin gene is expressed in RNA from all 
tissue homogenates investigated so far (Inoue, Tanizawa et al. 1998; Strom, Hortnagel 
et al. 1998). Higher mRNA steady state levels were detected in heart, brain, placenta, 
lung and pancreas. A more detailed expression analysis by Inoue and co-workers 
(1998) revealed that the expression in pancreatic tissue is restricted to the pancreatic 
islets, while expression in the exocrine pancreas is very low (figure 1.4). The high 
expression in pancreatic islet cells might explain that the earliest manifestation of 
Wolfram syndrome is IDDM. These observations led to the speculation that the 
Wolframin gene product might function in the survival of islet ß-cells and neuronal 
cells (Inoue, Tanizawa et al. 1998). 
The exact function of the Wolframin gene product is yet to be elucidated. In particular, 
no information could be derived from sequence searches in available DNA and protein 
databases. A Wolframin homologue was identified in mouse, which shows 83% 
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sequence similarity at the nucleotide level and 87% at the amino acid level (Strom, 
Hortnagel et al. 1998). A putative Wolframin homologue in Drosophila and C. 
elegans was also identified, however, lower eukaryotes like the yeast S. cerevisiae that 
can easily be manipulated on the genetic level, seem to lack Wolframin-like gene 
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Figure 1.4 mRNA expression pattern of Wolframin. A and C show Wolframin expression on various 
tissues, including isolated exocrine and islet fractions from pancreas. B and D show the respective 
actin expression. 
1.5 Hydropathy plot 
Secondary structure prediction programs (Rost, Casadio et al. 1995) suggest that 
Wolframin is a membrane spanning protein of 100.29 kDa consisting of a central 
hydrophobic portion flanked by two large hydrophilic domains, each of which 
comprises 300 to 350 amino acid residues. Predictions also suggest 9 transmembrane 
segments with an N-out/C-in topology. The functional role of the hydrophilic domains 
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is not yet known. However, the C-terminus appears to exhibit an important function as 
even the truncation of the last 8 amino acids appears to disrupt the protein function and 
result in a full-blown disease-phenotype (Hardy, Khanim et at. 1999). The majority of 
loss-of-function mutations are found on exon 8. Since this last exon also contains all 
of the transmembrane regions, disruptions here would most likely be important to the 
protein's stability. 
Five possible Asn-glycoslylation sites exist at positions 28,335,500,661 and 746. No 
known leader sequences targeting this protein to a particular function have been found 
based on amino acid information. For example, the dilysine (KK)/ diarginine (RR) 
and KDEL motifs which sort proteins into the ER are absent. There is no indication of 
a mitochondrial import signal or any other sequences targeting this protein to a specific 
sub-cellular localisation or function. 
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1.6 Objective of this work 
The Wolfram syndrome is a syndromic form of diabetes in which the gene product had 
not yet been characterised. This syndrome is especially interesting because it is a 
monogenic form of diabetes, presenting with a diverse array of neurodegenerative 
symptoms. The diabetes in DIDMOAD patients is non-autoimmune and is directly 
due to loss-of-function mutations in the Wolframin gene. The heterogeneity of 
mutations and varying levels of severity of the symptoms in these patients has shown 
no relationship to one another. Understanding the pathomechanisms behind the 
Wolfram syndrome will allow important insights into the molecular mechanisms 
involved in cell death and neurodegeneration. 
As a first step in understanding the function of the Wolframin gene, I set out to make 
antibodies to the respective protein. Antibodies enable one to determine the 
localisation of the encoded protein and are a valuable tool for determining how the 
protein itself interacts and its possible interaction with other proteins. Important to 
understanding a novel protein, is determining its cellular and sub-cellular localisation. 
Expression studies in the pancreas, will clarify if the Wolframin protein is expressed in 
the ß-cells. This will help explain if Wolframin is part of a pathway leading to the 
selective loss of ß-cells or if it has a function in ß-cells themselves. Determining the 
cellular localisation in the brain will show in which regions this protein is expressed 
and provide insight into how such diverse effects could be caused. Information from 
sub-cellular localisation studies can give important information on the possible 
function in the cell and finally answer the question, whether or not this really is a 
mitochondrial protein. 
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DIDMOAD is a very rare disease and adequate material to study the role of the 
Wolframin gene in its pathogenicity is difficult to obtain. It was, however, possible to 
obtain skin fibroblasts and blood from three Wolfram patients and other family 
members. Expression of the protein in these cells was observed and Wolframin 
positive and negative cells were used for various functional assays. 
The mouse homologue is 83% similar to the human and modelling diseases in mice is 
a good way to study underlying molecular mechanisms. Therefore, one of the 
approaches to determining the function of the Wolframin protein was to create a 
Wolframin knock-out mouse. Knock-out mice allow one to study a more rapid 
development of symptoms, examine molecular or physical changes at any stage and 
even effects of intervention. 
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Chanter 2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals: 
Chemicals were purchased from Roth, Merck or Sigma, unless otherwise stated. All 
locations refer to German cities unless otherwise stated. Restriction enzymes were 
bought from MBI Fermentas, Gibco and Promega. [alpha-32P] dCTP was purchased 
from Amersham Biosciences, Freiburg, Germany. 
pQE40 expression vector was purchased from Qiagen. AdvanTAge PCR cloning kit, 
pIRES and pIRES2EGFP were from Clontech. 
2.1.2 Materials supplied by others: 
ploxpneo-1 vector was kindly provided by Dr. Rolf Sprengel, Max Planck Institute for 
Medical Research, Heidelberg, Germany. Mitotracker Red mitochondrial selective dye 
was purchased by Molecular Probes, USA 
2.1.3 Primary antibodies 
PC2: polyclonal rabbit 
anti-Prohormone Convertase 2 
Chemicon International, CA, 
USA 
Penta-HIS: monoclonal mouse anti-6xHlStag 
ß-actin: monoclonal mouse anti- ß-actin 
PDI: monoclonal mouse anti- ER 
Golgi: monoclonal mouse anti-Golgi, 58 K 
TIM23: monoclonal mouse anti-mitochondria 
Qiagen, Hilden 
Sigma, München 
StressGen Biotechnologies, Canada 
Sigma, München 
BD Biosciences, Heidelberg 
Glucagon: monoclonal mouse anti-Glucagon Sigma, München 
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Insulin: monoclonal guinea pig anti-Insulin Sigma, München 
2.1.4 Secondary antibodies 
goat anti-mouse IgG FITC conjugate Sigma, München 
goat anti-mouse IgG TRITC conjugate Sigma, München 
rabbit anti-guinea pig IgG TRITC conjugate Sigma, München 
goat anti-rabbit IgG FITC conjugate Sigma, München 
goat anti-rabbit IgG TRITC conjugate Sigma, München 
anti-mouse IgG peroxidase conjugate Sigma, München 
anti-rabbit IgG peroxidase conjugate Sigma, München 
2.2 Solutions 
PBS: 137 mM NaCl, 2.7 mM KC1,4.3 mM Na2HPO4,1.4 mM KH2PO4. 
6x DNA loading buffer: 25% sucrose, 0.1 M EDTA, 0.05% (w/v) bromophenol blue. 
5x RNA loading buffer: 1 mM EDTA, pH 8.0,0.25% (w/v) bromophenol blue, 50% 
glycerol. 
20x SSC: 3M NaCl, 0.3M Na-citrate. 
TE: 10 mM Tris-Cl, pH 8.0,1 mM EDTA 
Church buffer: 1 mM EDTA, 0.25% phosphate buffer, 7% SDS. 
20x MOPS buffer: 400 mM morpholinopropanesulfonic acid (MOPS), 100 mM 
Na-acetate, 20 mM EDTA, pH 7.0 
Laemmli running buffer: 3.5 mM SDS, 25 mM Tris-acetate, 192 mM glycine. 
4x Laemmli loading buffer: 8% SDS, 40% glycerol, 240 mM Tris-Cl pH 6.8,0.08% 
(w/v) bromophenol blue, 20% 2-mercaptoethanol. 
HEPES lysis buffer: 10 mM HEPES, 250 mM sucrose, 1 mM EDTA. 
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Western blotting buffer: 20 mM Tris-acetate, 150 mM glycine, 0.02% SDS, 20% 
methanol. 
Tween TBS wash buffer: 10 mM Tris-C1,0.9% NaCl, pH 7.4,0.5% Tween 20. 
E. Coli lysis buffer (native): 100 mM NaH2PO4,10 mM Tris-Cl, 6M guanidine 
hydrochloride, pH 8. 
E. Coll lysis buffer (denaturing): 100 mM NaH2PO4,10 mM Tris-Cl, 8M urea, 
pH 8. 
50x TAE buffer: 40 mM Tris base, 5.71 % glacial acetic acid, 2 mM Na2EDTA. 
lOx TBE: 890 mM Tris base, 890 mM boric acid, 20 mM EDTA. 
2.3 Bacterial Culture and Manipulation 
2.3.1 Media for bacterial growth. Luria Broth (LB) medium and agar were 
purchased from Sigma. 
2.3.2 Preparation of transformation-competent bacteria. An overnight culture of 
E. coli bacteria: DH5a or XL-1 blue were inoculated into 100ml LB medium until 
approximately OD550 = 0.3 and centrifuged for 5 minutes at 1500 xg at 4°C. The 
bacterial pellet was resuspended in 30 ml ice-cold TFBI buffer (100 mM RbCI, 50 mM 
MnC12,30 mM KAc, 10 mM CaC12,15% glycerol, pH 5.8), stored on ice for 90 
minutes and centrifuged again for 5 minutes at 1500 xg at 4°C. The pellet was 
resuspended in 4 ml TFBII buffer (10 mM MOPS, 10 mM RbCI, 75 mM CaC12,15% 
glycerol) and aliquots of 20Uµ1 each were snap frozen in liquid nitrogen and stored at - 
80°C. TOP10F competent bacteria were purchased from Invitrogen. 
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2.33 Transformation of competent bacteria. DNA was added to 2O0µ1 of 
competent bacteria and stored on ice for 20 - 30 minutes and heat-shocked at 42°C for 
90 seconds and subsequently placed on ice for 2 minutes. The bacteria were then 
shaken at 37°C for 1 hour and plated on either LB-ampicillin or LB-kanamycin plates, 
containing 100 µg/ml antibiotic overnight at 37°C. Colonies were picked on the next 
day and grown overnight in 3 ml LB medium containing antibiotic with shaking at 
37°C. 2 ml of this culture was used for mini-preparation (see section 2.4.2). 
2.4 Nucleic Acid Methods 
2.4.1 Purification of DNA. DNA was purified using phenol/chloroform extraction in 
conjunction with ethanol precipitation. DNA was mixed at a 1: 1 ratio with a 
phenol: chloroform: iso-amylalcohol mixture (25: 24: 1), vortexed and centrifuged for 2 
minutes. The upper aqueous phase was pipetted into a fresh tube and mixed with 1 
volume of chloroform: isoamylalcohol (24: 1). The resulting DNA solution was 
precipitated by adding 1/10 the volume of Na-Acetate, pH 4.8 and 2.5 times the 
amount of 100% Ethanol. The mixture was stored at -80°C for 20 - 30 minutes and 
centrifuged for 10 minutes. The pellet was washed in 70% Ethanol, dried and 
dissolved in either TE or water. 
2.4.2 Plasmid Mini-preparations. 2 ml of an overnight culture were transferred to a 
2.0 ml Eppendorf tube and centrifuged at 16,000 xg for 30 seconds. The bacterial 
pellet was dissolved in 150 µl TE buffer and lysed for 5 minutes at room temperature 
in 150 µ1 lysis buffer (2% SDS, 0.4 M NaOH). 5001L1 neutralization buffer (0.9 M 
NaOAc, pH 4.9,0.5 M NaCI) was then added and incubated at -20°C for 5 minutes 
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before centrifuging for 10 minutes. 750 Al Isopropanol was added to 500µ1 of the 
supernatant and centrifuged for another 10 minutes to pellet the DNA. DNA was 
washed in 70% Ethanol, dried and redissolved in TE buffer containing 10µg RNase A 
2.43 Plasmid Maxi-preparations. The preparation was done using the Qiagen maxi 
kit. 200 ml of an overnight culture was sedimented at 5,000 xg for 10 minutes. The 
bacterial pellet was resuspended in 10 ml of Buffer B1 (100 µg/ml RNase A, 50 mm 
Tris-Cl, 10 mM EDTA, pH 8.0) and lysed with 10 ml buffer P2 (200 mM NaOH, 1% 
SDS). Neutralization was done with 10 ml buffer P3 (2.55 M KAc, pH 4.8) on ice for 
15 minutes in order to separate the SDS. This solution was centrifuged at 20,000 xg 
for 30 minutes, the supernatant was transferred to a fresh tube and centrifuged again 
for 15 minutes. This new supernatant was loaded onto an equilibrated Qiagen maxi 
column. The column was washed twice with buffer QC (1 M NaCl, 50 mM MOPS, 
15% EtOH, pH 7.0) and eluted with 15 ml QF buffer (1.25 NaCI, 50 mM MOPS, 15% 
EtOH, pH 8.2) and precipitated with 10.5 ml isopropanol. After centrifugation at 
15,000 x g, the DNA pellet was washed in 70% EtOH, dried and resuspended in TE. 
2.4.4 Agarose gel electrophoresis. Agarose gels from 0.8% to 2% were poured, 
depending on the size of DNA fragments to separate. Agarose was dissolved in either 
TAE or TBE by heating in a microwave oven. Ethidium bromide was added after the 
gel had cooled down to 60°C to a final concentration of 0.5µg/ml in order for the DNA 
to be photographed under UV light of 320nm. For quantitative RT-PCR, VistraGreen 
(Amersham Biosciences) was added to the loading buffer and no ethidium bromide 
was used. 6x loading buffer was added to the respective DNA before loading. 
VistraGreen is a chemical that emits fluorescence when it interacts with DNA at a 
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level that is more indicative to the relative amount of DNA then the intercalation of 
ethidium bromide. Quantification was done using a Flourescent Image Analyzer 2000 
(FLA) (Fujifilm Raytest). The gels were run between 80 and 120V. Running buffer 
used was used was the same as the buffer to dissolve the agarose. 
2.4.5 Isolation of DNA fragments. DNA was loaded onto a 1% Agarose Gel in TAE 
buffer and the fragment to be isolated was cut out with a scalpel after observation with 
UV light. DNA was isolated using Amersham's GFX PCR DNA and Gel Band 
Purification Kit according to the manufacturer's instructions. 
2.4.6 Restriction enzyme digestions. Restriction enzyme digests were performed 
according to the manufacture's instructions with commercially available 
endonucleases. Buffers were used as directed for single digests. Double digests were 
done in one suitable buffer for both, otherwise DNA was digested with the lowest 
ionic strength buffer first and the higher ionic strength buffer was added subsequently. 
2.4.7 Sub-cloning and ligation. DNA to be subcloned was either cut from an 
existing vector or PCR amplified and cloned into the AdvanTAge PCR cloning kit 
(Clonetech) and cut out using either the two flanking EcoRI sites or using restriction 
enzymes on either side of the EcoRI sites. Ligation was performed with 1 Al T4 ligase 
(400,000 units/ml) (New England Biolabs) in a 10 µ1 reaction at 14°C overnight. 
Ligated DNA was then used to transform competent bacteria. 
2.4.8 DNA Sequencing. The BigDye terminator cycle sequencing kit was used in 
connection with an ABI PRISM 310 Genetic Analyzer (Perkin Elmer). Either PCR 
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products or whole plasmids were used as template for the cycle sequencing reaction. 
The cycle sequence reaction was done for 25 cycles of 10 seconds at 96°C, 5 seconds 
at 56°C - 59°C and 4 minutes at 60 T. The DNA was then precipitated at room 
temperature for 15 minutes. Pellets were dissolved in 13 µl template suppression 
reagent and heated at 95°C for 5 minutes. Samples were then loaded and run 
according to manufacturer's instructions. 
2.4.9 Southern blotting. 20 - 50µg DNA was digested with a respective restriction 
enzyme overnight and the DNA was ethanol precipitated to an amount, which can be 
easily loaded on an agarose gel. A 0.8% gel was poured and run for 4-5 hours at 95V 
until loading buffer had gone 15 cm. The gel was then washed twice for 15 minutes in 
denaturing buffer (500 mM NaOH, 1.5 M NaCl) and 30 minutes in neutralization 
buffer (500 mM Tris base, 1.5 M NaCl) and rinsed in 20xSSC. Transfer was 
performed overnight in 2OxSSC by capillary transfer using the Whatman 3MM filter 
paper wick method (current protocols in molecular biology). After transfer, the gel 
and Nylon membrane Hybond N+ were checked by observation under UV light. The 
membrane was briefly washed in water and dried for 30 minutes at 37°C and 
subsequently linked in a UV oven at 1200 µjoules x 100. Radioactive labelled probes 
were hybridised to the blot in church buffer overnight at 65°C in a glass rotating tube. 
On the next day, the filters were washed at 65°C in 2x SSC/0.1% SDS and then in lx 
SSC/0.1% SDS. If this washing was not sufficient, 0.5x SSC/0.1% SDS was used. 
2.4.10 Production of radiolabelled probes. DNA probes were made using the 
Rediprime kit from Amersham. In short, 40 ng DNA was diluted in a total volume of 
45 µl TE and denatured for 10 minutes at 95°C. After cooling on ice, the sample was 
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added to the Rediprime tube (containing the Klenow fragment of DNA polymerase I, 
nucleotides and buffer). After gentle mixing, a-32P-dCTP was added and incubated for 
10 minutes at 37°C. Unbound radioactive nucleotides were filtered over a Sephadex- 
050 column. All of the flow-thru was added to the hybridization solution. 
2.4.11 Preparation and analysis of RNA. RNA isolation from mouse tissues was 
performed using a Guanidiniumisothyiocyanate (GTC) denaturing solution (4 M 
guanidine thiocyanate, 25 mM sodium citrate, 0.5% Sarkosyl and 0.1 M 2- 
mercaptoethanol) and isolation from cells was done using Trizol Reagent (GIBCO). 
The desired tissue was homogenized in 2 ml GTC denaturing solution using a glass 
teflon homogeniser. 0.1 ml of 2M sodium acetate, pH 4.0 was added and mixed. 0.1 
M Phenol was added and mixed again, after which 0.2 ml chloroform was added and 
mixed by vortexing. The solution was incubated on ice for 15 minutes. The tube was 
then centrifuged for 20 minutes at 10,000 x g. The aqueous phase was transferred to a 
clean tube. Adding 1 ml isopropanol and incubating for 30 minutes at -20°C 
precipitated the RNA. The RNA was pelleted by centrifugation for 10 minutes at 
10,000 xg at 4°C and washed in 75% Ethanol for 10 minutes at room temperature to 
dissolve remaining guanidine. DEPC-treated water was added to the air-dried pellet 
and dissolved at 56°C. RNA was then stored at -70°C. Cells were washed in PBS and 
scraped in Trizol reagent. RNA was prepared according to the provided protocol from 
GIBCO. 
2.4.12 Isolation of poly A+ RNA. Oligotex mRNA mini kit from Qiagen was used 
according to manufacture's directions. Elution was done using 70°C OEB buffer. The 
first eluate was mixed with 10141 fresh OEB buffer, reheated to 70°C and loaded onto 
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the column for a second elution. For microarray analysis, the RNA was subsequently 
precipitated with addition of 5mg/ml glycogen. 
2.4.13 Quantitative RT-PCR. Total RNA was prepared from mouse tissues using the 
GTC method and from cells using Trizol. cDNA was synthesized from total RNA 
using SUPERSCRIPT II (Gibco). 5 µg of RNA was reverse transcripted with Oligo 
dT according to the instructions. cDNA was stored at -20°C until use. RT-PCR was 
initially performed at varying cycles to determine the exponential range. For each 
sample, ß-actin was also amplified at the same time. Quantification of bands was done 
using VistraGreen and observing on an FLA (refer to section 2.4.4). Band intensity of 
products was normalized to that of ß-actin and this relative amount was then compared 
between samples. All RT-PCRs were loaded twice to reduce possible inaccuracies due 
to loading. Reverse transcriptase was repeated three times and a single PCR was 
performed for each cDNA produced. 
2.5 Cell Culture and Maniuulation 
2.5.1 Tissue culture media. All media and media supplements were purchased from 
Gibco. A penicillin/streptomycin (P/S) mixture was added to all media at an end 
concentration of 100 U/ml and 100 pg/ml respectively. Amphotericin B was 
frequently added at a concentration of 2.5 µg/ml. Trypsin/EDTA and PBS were also 
purchased from Gibco. 
2.5.2 Tissue culture. Human primary fibroblasts and COS-7 cells were grown in 
Dulbecco's modified Eagle's medium (DMEM) containing Glutamax supplemented 
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with 10% fetal calf serum (FCS). OTC-tet cells were grown in DMEM plus Glutamax 
supplemented with 2.5% FCS and 15% horse serum. In-RI-G9 a-cells were grown in 
RPMI medium supplemented with 10% FCS. Embryonic Stem (ES) cells were grown 
in DMEM supplemented with 0.1 mM non-essential amino acids, 1 mM Sodium 
Pyruvate, 10-6 M ß-mercaptoethanol, 2 mM L-glutamine, 15% FCS, 1% P/S and 1000 
U/ml Leukemia Inhibitory Factor (LIF). All cells were incubated at 37°C and 5% 
C02. 
Adherent cells were passaged by removing medium, washing in PBS, adding trypsin at 
1/3 the volume needed for growth and incubating 3- 10 minutes at 37°C. An equal 
volume of medium was added to the detached cells and this mixture was centrifuged 
for 5- 10 minutes at 1000 x g. The pellet was resuspended in fresh medium and 
diluted 1: 2 - 1: 5 depending on cell type and confluence. Cells were frozen for long- 
term storage by first trypsinizing and then resuspending in 1 ml per 75 cm2 flask of 
freezing solution containing normal growth medium supplemented with 10% 
dimethysulfoxide (DMSO). This solution was transferred to cryotubes and stored 
overnight at -80°C before being placed in liquid nitrogen (-196°C) to be stored 
permanently. 
2.5.3 Transfection. 4x 104 cells were seeded per well of a 24-well plate the day 
before transfection and grown overnight in normal medium without 
Penicillin/Streptomycin (P/S). For 24-Well plates, other sizes were scaled up or down 
proportionately to the surface area, 0.8 µg DNA and 2 µl Lipofectamine 2000 
(Invitrogen) were each diluted in 50 µl medium containing no serum and no P/S. 
These two solutions were mixed together within 5 minutes and let to sit at room 
temperature for 30 minutes, during which the cells were washed in serum-free 
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medium. After 30 minutes, 150 µl serum-free medium was added, gently mixed and 
overlaid onto washed cells. After 5 hours of incubation, another 250 µl of medium 
was added containing twice the normal serum but no P/S. Cells were harvested for 
western blot or fixed for immunofluorescence after 24 hours. If pIRES2egfp vector 
was used, cells were observed under a fluorescence microscope for transfection 
efficiency. 
2.6 Recombinant Protein Production 
2.6.1 Expression of pQE vectors in E. Coli. pQE40 vectors, containing either N- or 
C- terminal Wolframin sequences were used to express recombinant protein. Positive 
clones were inoculated in 30 ml LB-Amp culture overnight. On the next day, the 30 
ml culture was over-inoculated into 300 ml LB-Amp medium and grown to an OD6w = 
0.2. At this point, gene expression was induced with 1mM Isopropylß_a 
Thiogalactopyroanoside (IPTG) and grown for an additional 3-4 hours to an OD6W = 
0.6-0.8. Cells were harvested and the pellet dissolved in 4m1 of either native or 
denaturing lysis buffer. The pellet was then frozen overnight at -20 °C or for longer 
periods of time at -80 °C. Lysozyme was adding after thawing and incubated for one 
hour on ice. Cells were opened by subjection to ultrasound three times at 30 seconds 
each with one minute in between. Cell debris was pelleted at 20,000 xg for 20 
minutes at 4 °C. Supernatant was transferred to a separate tube and the pellet was 
dissolved in 4m1 of lx Laemmli buffer. Both the pellet and supernatant were observed 
on SDS-PAGE gel. If the protein was not over-expressed in the soluble fraction, lysis 
was attempted in a denaturing buffer. 
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2.6.2 Ni-NTA column purification. 1 ml of Qiagen Ni-NTA gel was pipetted into a 
12 ml tube and centrifuged at 100 xg for two minutes and the ethanol storage solution 
was discarded. The gel was then washed twice in 1 ml lysis buffer before being 
resuspended in 1 ml lysis buffer and loaded onto a column. At 4°C, 15 ml of lysis 
buffer was run over the column before exchanging the buffer with the protein sample. 
The column was reloaded twice with flow thru to assure maximum binding capacity. 
Washing was done with 10 ml lysis buffer + 20mM imidazole. Wash buffer was then 
exchanged with 10 ml of lysis buffer containing 200mM imidazole to elute bound 
protein. The elutates were collected in 1 ml volumes in Eppendorf tubes and saved for 
SDS-PAGE gel analysis and western. Eluates, which contained the expressed protein 
were pooled and used to immunize rabbits. 
2.7 Protein Methods 
2.7.1 Separation of proteins on SDS-PAGE. Protein separation was done according 
to the Laemmli method. Protein samples were boiled for 5 -10 minutes in Laemmli 
loading buffer containing 5% ß-mercaptoethanol as reducing agent. Either 10% or 
12% polyacrylamide gels plus stacking gel were poured into BioRad mini protean 3 
plates and electrophoresed using this system. Electrophoresis was done at 120V for 
1.5 hours. Coomassie stained gels were incubated in 0.25ß6 (w/v) Coomassie Brilliant 
blue R250 (Serva) in 40% methanol and 10% acetic acid overnight at 4°C. Destaining 
was done in 10% acetic acid and 30% methanol. 
2.7.2 Western blot and detection. Those gels to be blotted were placed on 3 layers of 
3MM Whatmann paper pre-wetted in blot buffer (20 mM Tris, 150 mM glycine, 
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0.02% SDS and 20% methanol). Pre-wetted Protran BA 85 cellulose nitrate 
(Schleicher and Schuell) was placed on the gel followed by an additional 3 layers of 
pre-wetted Whatmann and blotted in a semi-dry electroblotter (PeqLab) for 1.1 - 1.5 
hours at 210 mAmp. Blots were stained in Ponceau solution for 20 minutes and 
washed in water to observe protein bands. After blots were dry, they were blocked for 
30 minutes in 5% non-fat dried milk in tween TBS. Antibody incubation was done at 
4°C overnight. The membrane was washed in Tween-TBS three times at 10 minutes 
each and incubated at room temperature with horse radish peroxidase-conjugated anti- 
rabbit or anti-mouse IgG, depending on source of primary antibody. The membranes 
were washed for 4 times at 10 minutes each in Tween-TBS and detected using the ECL 
system (Roth). 
2.7.3 Protein extraction. Protein extracts from tissue culture cells were prepared by 
dissolving cell pellets at a concentration of 1x 103 cells/Al in lx Laemmli loading 
buffer and boiling them before loading 201zl (= 2x 104 cells) on an SDS-PAGE gel. 
Homogenate protein solutions from mouse tissues were prepared by homogenizing in 
HFS buffer (10 mM HEPES, 250 mM sucrose, 1 mM EDTA, 1 mM PMSF). Protein 
concentration was determined using Rotiquant solution from Roth, measuring OD 550 
nm. 
2.7.4 Sub-cellular fractionation. Tissue was extracted and kept in ice-cold HES 
buffer. The tissue was then weighed and homogenized in 10 ml LIES buffer per gram 
of tissue. Homogenization was done with 6 strokes of a glass/teflon potter and 2 
strokes in a glass douncer with a loose fitting and once with a tight fitting. This 
homogenate was centrifuged at 600 xg for 10 minutes to pellet out cell debris and the 
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nuclear fraction. The supernatant was centrifuged 3 times at 1,000 xg for 10 minutes 
each to ensure that no nuclear debris would contaminate the mitochondrial fraction 
(Mt). Pellets were pooled from the second and third centrifugation at 1,000 x g, 
washed and used as the nuclear pellet (Nuc). The supernatant was then centrifuged at 
8,000 xg for 10 minutes to pellet the mitochondrial fraction. The resulting pellet was 
then washed in 5 ml HES buffer and centrifuged at 10,000 x g. The Mt pellet was then 
dissolved in 2 ml HES buffer and purified over a sucrose gradient of 1.2 M and 1.5 M 
sucrose by ultra centrifugation at 40,000 xg for 25 minutes. The band at the interface 
was pipetted out into a 1.5 ml tube, centrifuged for 15 minutes at full speed in a table 
top centrifuge at 4°C and the pellet resuspended in TE buffer and used as the 
mitochondrial fraction (Mit). The post-mitochondrial supernatant was centrifuged at 
100,000 xg for 1 hour to separate the microsomal fraction (Ms) from the cytosol 
fraction (Cyt). Protein concentration was measured using the Bradford method 
(Bradford 1976) and an equal amount of each fraction was loaded onto a western blot. 
2.8 Histological Techniques 
2. &1 Tissue sections. Tissues were placed in a 10rad tube containing 4% 
Paraformaldehyde (-2ml) and incubated for 2h at 4°C and then overnight at 4°C in 
30% Sucrose in PBS. Tissues were then snap frozen in aluminium foil in liquid 
nitrogen and stored at -80°C. Sections were sliced at 5 µm on a Cryostat and stored at 
-20 °C. 
34 
2.9 Immunoloeical Methods 
2.9.1 Immunohistochemistry. Frozen slides were taken out of -20°C and dried at 
room temperature for approximately 15 minutes. Dried slides were fixed for 10 
minutes in acetone. Fixed slides were dried for 1 hour at room temperature. They 
were then washed in PBS and blocked for 30 minutes at room temperature in a humid 
chamber with either goat serum or BSA at a 1: 50 dilution in PBS depending on source 
of primary antibody. After blocking, slides were washed twice for around 5 minutes 
each time in PBS. Next, the primary antibody was added at varying concentrations in 
1: 200 blocking serum and incubated overnight in a humid chamber at 4°C. On the 
next day, the humid chamber was allowed to equilibrate to room temperature for 15 
min. The slides were then washed in PBS and the secondary antibody was added and 
incubated at room temperature for 30 min to 1 hour. Afterwards, the slides were wash 
in PBS and fixed with Fluoromount-G, Southern Biotechnology Associates, Inc., USA. 
2.9.2 Immunofluorescence. Cells were seeded on either 8-Well or 4-Well chamber 
slides (Nunc) to approximately 80% confluency. Cells were washed in PBS and fixed 
for 10 minutes at room temperature with 4% Paraformaldehyde in PBS. After washing 
twice in PBS, permeablization was done with 0.2% Triton X-100 in PBS for 5 minutes 
and then for an additional three changes over 5 minutes. 50 - 200 Al of primary 
antibody, diluted in PBS with 3% BSA and 0.2% Triton X-100 was added to the 
permeablized cells and incubated for either 1 hour at room temperature or overnight at 
4°C. Chamber slides were washed again in three changes of 0.2% Triton X-100 in 
PBS over 5 minutes. Either FITC or TRITC conjugated secondary antibody was added 
at a dilution of 1: 50 for 20 - 30 minutes at room temperature, washed for an additional 
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5 minutes with 0.2ß6 Triton X-100 in PBS, mounted with fluoromount and observed 
under a fluorescence microscope (LEICA DM IRB, Leica Microsystems Wetzler 
GmBh, Germany). The SPOT program version 3.4 (Diagnostic Instruments, Inc. ) was 
used to photograph and analyse all immunofluorescence and immunohistochemistry 
specimens. Co-localisation was done by merging individual FITC and TRITC pictures 
of the same region after optimising each using the histogram option. 
2.10 Transeenic Techniques 
Cloning of the Wolframin mouse knock-out construct. Before genomic sequences 
were available publicly, the GenomeWalker kit (Clonetech) was used to amplify 
genomic sequences from the intron between exon 7 and exon 8. The four 
GenomeWalker libraries containing the adaptor segments were amplified with the 
given API forward primer, which annealed to the adaptor sequence and a reverse 
primer in the extreme 5' region of exon 8. A nested PCR was performed with AP2 and 
a second reverse primer from exon 8. Positive PCR products were isolated and 
sequenced. The sequences from these products were used to make new reverse 
primers and the procedure repeated again with the same library DNA. This method 
was used to sequence 1500 bp of genomic DNA. However, this turned out not to be 
long enough. Later, sequences available from Celera were used to amplify a 5' 
segment of 5.3 kb. Amplification was done using the longExpand kit from Boehringer 
Mannheim. This was cloned into an AdvanTAge PCR cloning vector and cut out with 
the 2 flanking EcoRI sites. This was subsequently cloned into an EcoRI site located on 
the ploxpneol plasmid 5' from a PGK-1 promoter, neomycin gene and a PGK-1 
terminator region. The 3' region from exon 8 was amplified, sequenced and cloned 
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into pTAdvantage and subcloned in a pBSKII vector at the EcoRI site contained in the 
multiple cloning site. The 5' region including the neomycin gene was cut out using 
two flanking Xba1 sites and subcloned into the pBSKII vector containing the 3' 
segment. Orientation was checked by restriction digest. 
2.10.1 DNA transfer. 200µg of the Wolframin knock-out mouse construct was 
digested with XhoI, precipitated and purified over a chromaspin column 1000, 
exchanging the buffer from TE to PBS. The linearized DNA was electroporated at 240 
V, 500 µF into R1-FS cells and the cells transferred to 10 cm dishes containing 0.1% 
gelatine. Two days after electroporation, medium was exchanged with fresh medium 
containing 200 µg/ml G418. After 8- 10 days 600 resistant colonies were picked. 2- 
3 drops of trypsinized cells from each clone were pipetted into individual wells of 96- 
Well plates containing a layer of mitomycin inactivated feeder cells and the rest was 
used for DNA preparation. 
2.10.2 Screening of ES clones. ES cell clones were pooled at 6 colonies per 1.5 ml 
tube and DNA isolated by first centrifuging the tubes of ES cells at maximum speed 
for 45 seconds and washing in 500µl PBS. The pellet was then resuspended in 501t1 
PCR-grade water and boiled for 10 minutes. Cell debris was digested by incubation in 
50 µg of Proteinase K at 55°C for 95 minutes. DNA was denatured by boiling for 10 
minutes and was stored at -20°C until used for PCR analysis. Positive pools were 
screened by nested PCR amplifying with 2 successive forward primers from the neo 
gene to 2 reverse primers outside of the 3' end of the construct. ES cells from positive 
pools were propagated from 96-Wells to 24-Wells, pipetting out 50µ1 for another DNA 
preparation. The DNA from these individual clones was amplified as before and 
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positive clones identified. Cells from positive clones were then transferred to a 6-Well 
and eventually to 10 cm dishes. Cells from a single 10 cm dish were frozen for long- 
term storage and DNA was isolated for southern analysis from another 10 cm dish. 
2.10.3 Isolating DNA from ES cells. Cells were preplated onto gelatine-coated plates 
for 20 minutes at 37° to remove feeder cells. Feeder cells will attach themselves to the 
bottom of the plate in this time, but ES cells will not have attached themselves to the 
feeder cells yet. The plate was then rinsed with its ES cell-containing medium and 
transferred to another gelatine-coated plate. The preplating was repeated, this time for 
only 10 minutes. The ES cell-containing medium was then centrifuged and 
resuspended in 4.4m1 TENPK buffer (50 mM TrisCl, 100 mM EDTA, 100 mM NaCl, 
100µg/m1 Proteinase K) and mixed with a pasteur pipet. 0.6 ml 10% SDS was added 
and mixed gently by inverting the tube. The DNA was digested for 2 -3 days at 55°C 
with gently rocking. After this time, DNA was isolated by phenol/chloroform 
extraction and the precipitated DNA was spooled on a glass rod, washed in 70% 
Ethanol, resuspended in TE and used for Southern analysis. 
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Results 
Chapter 3. Wolframin expression in the NOD mouse model 
Wolframin mRNA expression has been observed in all tissues tested with pancreatic 
expression being restricted to the endocrine pancreas (Inoue, Tanizawa et al. 1998; 
Strom, Hortnagel et al. 1998). It is not known why Wolframin mRNA is expressed in 
so many different tissues, but the functional defect of the Wolframin protein targets 
primarily neuroendocrine functions. In order to investigate this further, its expression 
during the progression of diabetes in the well-established nonobese diabetic (NOD) 
mouse model was studied. 9 female mice of the same age (provided by Dr. Helga 
Rothe, Institute for Diabetes Research) were used in this experiment. This mouse 
model was chosen because the main symptom in WS is young onset diabetes mellitus. 
Even though the NOD mouse model is based on an immune-mediated type 1 diabetes 
and the diabetes in DIDMOAD is non-autoimmune, both are based on a loss of 
pancreatic ß-cells. This made it reasonable to study whether or not Wolframin 
expression is changed during a regulated loss of ß-cells in cyclophosphamide induced 
diabetes in NOD mice. It is largely unknown how cyclophosphamide accelerates 
diabetes, however, it has been postulated that the drug depletes protective T-cells 
(Yasunami and Bach 1988). Many tissues were examined for a possible effect on 
Wolframin expression during diabetes. The tissues tested were: brain, heart, kidney, 
liver, lung, pancreas and spleen. RT-PCR was performed on day 0, day 3 and day 9 
after induction of NOD mice for diabetes with cyclophosphamide. Gel bands were 
quantified using the Advanced Image Data Analyzer (AIDA) program version 1.3. 
Expression for Wolframin was normalised to quantified ß-actin bands. The only 
tissues that showed any difference between day 0 and day 9 were the brain and 
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pancreas (figure 3.1). These are also the two tissues affected by WS. Thus, inducing 
NOD mice for diabetes with cyclophosphamide causes a change in Wolframin mRNA 
expression in neuroendocrine tissues. 
Gene Expression in enhanced NOD mice 
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Figure 3.1 RT-PCR of cyclophosphamide treated NOD mice. Expression of either Wolframin or 
Insulin was normalised to 0-actin. Tissues were taken from two separate mice at each time point and 
three RT-PCR's were performed for each mouse. 
To determine if the decrease in the pancreas was due to the destruction of ß-cells, 
insulin expression in the same pancreata was observed. Unfortunately, the decrease in 
insulin was not as pronounced as the decrease in Wolframin, however, compared to 
day 0, there was some decrease in expression. 9 days after induction for diabetes, 
expression in insulin-producing ß-cells decreased by 21.5%. Therefore, Wolframin 
expression decreases with a decrease in ß-cells. 
day 0 day 3 day 9 day 0 day 3 day 9 day 0 day 3 day 9 
11 
Brain Pancreas 
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Expression in the brain was found to increase by 120% 9 days after induction for 
diabetes. Considering that the neurodegenerative damage follows the diabetes in WS 
patients, it is theoretically possible that the neurological symptoms are a consequence 
of the diabetic conditions in neuronal tissue. However, the expression and modulation 
of expression of the Wolframin gene in neuronal tissue at least make a direct effect 
possible. Determining specifically where the Wolframin protein is expressed, as will 
be discussed in chapter 6, may provide further clues as to a possible function. 
Chanter 4. Cell model of Wolframin and mRNA expression 
In order to make it possible to study the effects of the mutated Wolframin gene, Dr. 
Cathy Burson (University of Iowa, USA) kindly provided us with human primary skin 
fibroblasts from a Wolfram patient (Patl4) and a sibling (Sib13). DNA isolated from 
blood samples was obtained from the patient's mother and father in addition to the 
sibling. Fibroblast cells and DNA from another Wolframin patient, PatEC, were also 
obtained from Michael Ristow (German Institute for Nutrition, Berlin). Blood or cells 
from relatives of this patient were not available. 
4.1 Sequence analysis 
Dr. Sabine Hofmann (Institute for Diabetes Research, Munich, Germany) had already 
sequenced Pat14 DNA for mutations in exons 2-8. Two possible disease-causing 
mutations were found in exon 8. The regions where mutations had already been found 
in Pat14 were then sequenced in DNA from Sib13 and both parents in order to 
determine which mutations were enough to cause the WS phenotype. Sequence 
analysis revealed a typical case of Wolframin mutations: Pat14 is compound 
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heterozygous for two separate mutations. One allele contains a nonsense mutation 
leading to an early stop codon at 371aa instead of 890aa and the other allele contains a 
missense mutation exchanging a Tryptophan for an Arginine (R629W). All other 
family members were positive for only a single mutation (table 4.1). 
DNA from PatEC was sequenced for mutations in the entire exon 8 region. This 
patient was found to contain a homozygous single insertion at 343aa leading to an 
early stop codon at 395aa. In addition, a missense mutation was found at 389aa, which 
exchanges a Histidine for an Aspartic acid (D389H) (Table 4.2). This patient should 
not produce any full length Wolframin protein and was a good negative control for 
future protein analyses. 
Nlutation Patient 14 Sister 13 Mother Father 
W371X Heterozygous Heterozygous 
early stop 
R629W Heterozygous Heterozygous Heterozygous 
Missense 
Table 4.1 Mutation analysis of a Wolfram patient and parents. Patient 14 is compound heterozygous 
for two different mutations; one leading in a truncated protein and the other is a missense mutation. Her 
first grade relatives in comparison are only heterozygous for a single mutation. 
Table 4.2 Mutation analysis of Wolfram patient PatEC. This patient is homozygous for a single base 
insertion at 343aa, leading to an early stop codon at 395aa. The resulting protein is truncated to only 
44% of its normal length. 
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Figure 4.1 RT-PCR of fibroblast cells from DIDMOAD patients and controls. Wolframin expression 
was normalised by ß-actin. Each RT-PCR was repeated three times. The gel picture shows a single 
representative RT-PCR result. 
4.2 mRNA expression 
It had already been shown that Wolframin mRNA is ubiquitously expressed in many 
tissues (Inoue, Tanizawa et al. 1998; Strom, Hortnagel et al. 1998). However its 
expression in fibroblast cells and other cell lines had not been observed. Therefore, 
Wolframin mRNA expression in fibroblast cells from these patients and from 
fibroblasts from control individuals was analysed with RT-PCR (figure 4.1). Primers 
used were: human Wolframin forward: 5'-AAA GAG GAA GAG GAA GTA GCC 
GAT GG-3', human Wolframin reverse: 5'-GAG GCT GAC GTT GAG GAT GAT 
GAA GT-3', ß-actin forward: 5'-ATC TGG CAC CAC ACC TTC TAC AAT GAG 
CTG-3' and ß-actin reverse: 5'-CGT CAT ACT CCT GCT TGC TGA TCC ACA 
TCT-3'. Wolframin mRNA expression was found in fibroblast cells, however, no 
notable differences were seen in expression between cells from controls and WS 
patients. Therefore, these mutations do not affect stable mRNA expression in addition 
Z 0. M jcý 
Control Sibl3 Pat14 PatEC 
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to their expected effect on the structure and function of the Wolframin protein. The 
fact that Wolframin is expressed in fibroblast cells, indicated that these cells could be 
suitable for functional analysis. 
Chanter S. Production of antibodies to recombinant urotein and DeDtides 
The Wolframin cDNA sequence encodes for a polypeptide of 890aa, with a predicted 
molecular mass of 100.29 kDa. Figure 5.1 shows the hydrophobicity plot of the 
deduced amino acid sequence. A transmembrane protein is predicted which 
transverses the membrane nine times. The protein contains, therefore, three structural 
domains, hydrophilic N- and C- terminal regions and a central hydrophobic core 
spanning the region from 330 - 650aa. Protein structure prediction programs (Stoffel, 
Duker et al. 1993; Rost, Casadio et al. 1995) preferentially placed the N-terminal 
hydrophilic part on the extracytoplasmic side and the C-terminal part on the 
intracytoplasmic side. This deduced amino acid structure contains no sequences 
targeting the protein to any function or cellular compartment, nor is it homologous to 
any known protein. In order to gain insight into this novel protein, antibodies were 
made to recognise its N- and C- terminal regions. Antibodies raised against both 
peptides and recombinant proteins were used in this work. 
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Figure 5.1 Prediction of possible transmembrane helices. 9 transmembrane helices were predicted from 
the Wolframin amino acid sequence. 
5.1 Production of recombinant proteins as antigens for immunisation 
The advantage to making antibodies against recombinant protein is that more epitopes 
are presented to the immune system and the antibody can recognise even the denatured 
state. However, in the case of such a large transmembrane spanning protein, it would 
be very difficult or even not possible to produce a recombinant protein to the entire 
sequence. Therefore, due to their hydrophilic nature, the N- and C- terminal regions 
were chosen as targets to be incorporated into recombinant protein to be used as 
antigens for antibody production. In these hydrophilic regions, the human and mouse 
sequences are relatively conserved (figure 5.2). The N-terminus region chosen for 
antigen production spans 1- 295aa and is 83% identical to the mouse sequences at the 
amino acid level. The C-terminus region spans 625 - 890aa and its amino acid 
sequence is 91% similar to the mouse amino acid sequence. 
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human: RSRLNATASLEQERSE---------------- VRDAAAPAEPQAQHTRSRERADGTGPTR 
mouse: RARLNATASLEQDRIEPPRAPRPQADPSAGRSAGEAAAP-EPRAPQTGSREETDRAGPRK 
human: GDMEIPFEEVLERAKAGDPF. AQTEVGKHYLQLAGDTDEELNSCTAVDWLVLAARQGRREA 
mouse: ADVEIPFEEVLERAKAGDPKAOTEVGKBYLR. LAIIDADEELMSCSJLVkV ! I! LAAROGnRMA 
human: 
mouse: 
human: 
mouse: 
human: SLFLQ------- 
mouse: DNLFLQDEDEDED 
human: THHINALIFFFIISNLTIDFFAFFIPLVIFYLSFISMVICTLKVFQDSKAWENFRTLTDL 
mouse: THHINALIFFFIISNLTIDFFAFFIPLVVFYLSFVSNVICTLKVFQDSKAWENFRTLTDL 
human: 
mouse: 
human: 
mouse: 
human: VSVPC-------- 
mouse: VSLPCLLYVYLFY 
human: IGYFLFLFALPI---------- 
mouse: IGYFLFLFALPILVAGLALMGT 
human: VGMVKSLTRSSMVKLILVWLTAIVLFCWFYVYRSEGNIcVYNSTLTWQQYGALCGPRAWKE 
mouse: MGMVXSLTKSSMVKLILVWLTAILLFCWFYVYRSEGMKVYNSTLTWQQYGYLCGPRAWKE 
human: TNMARTQILCSHLEGHRVTWTGRFKYVRVTDIDNSAESAINNLPFFIGDWMRCLYGEAYP 
mouse: TNNARTQILCSHLEGHRVTWTGRFKYVRVTEIDNSAESAINNZ+PFFLGDWNRCLYGEAYP 
human: ACSPGNTSTAEEELCRLKLLAKHPCHIKKFDRYKFEITVGMPFSSGADGSRSREEDDVTK 
mouse: SCSSGNTSTAEEELCRLKQLAICHPCHIRKFDRYKFEITVGMPF--GTNGNRGHEEDDITK 
human: DIVLRASSEFKSVLLSLRQGSLIEFSTILEGRLGSKWPVFELKAISCLNCMAQLSPTRRH 
mouse: DIVLRASSEFKDVLLNLRQGSLIEFSTILEGRLGSKWPVFELKAISCLNCMTQLSPARRH 
human: VKIEEDWRSTVHGAVK----------LSAA 
mouse: VXIEQDWRSTVHGALKFAFDFFFFPFLSAA 
Figure 5.2 Alignment of the human and mouse Wolframin amino acid sequences. Underlined 
sequences indicate transmembrane regions. 
These two regions were PCR amplified and cloned into pQE40 (Qiagen) expression 
vectors using the sites BamHI and HindIII. Both enzymes do not cut Wolframin 
cDNA and were therefore introduced on the PCR primers. N- or C-terminal regions 
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were cloned in frame with the start codon located upstream from the His tag located on 
the pQE40 vector. pQE40 plasmids utilise the phage T5 promoter coupled with two 
lac operator sequences, which increase lac repressor binding to regulate the T5 
promoter. The 6x His tag located on the 3' end of the multiple cloning site (MCS), 
allows for immobilisation of the expressed protein by binding to Ni-NTA agarose 
columns. 
PQE40 vectors containing either C-terminal (WmrecC) or N-terminal (WmrecN) 
sequences were inoculated into E. coli and induced for expression of the respective 
protein with IPTG. In order to test for expression, aliquots of the pellet and 
supernatant (SN) were loaded onto a 12% SDS gel. As a control, a parallel experiment 
was done without induction with IPTG. Neither WmrecC nor WmrecN protein was 
detected when cells were lysed under native conditions. Instead, WmrecN and 
WmrecC both formed insoluble inclusion bodies and were impossible to solubilise 
without using 8M urea as a denaturing agent. In an attempt to solubilise the 
recombinant protein, clones were inoculated in E. coli and induced as before. The E. 
coli pellet was dissolved in 4 ml PBS and sonicated three times at 30 seconds each. 
The culture was divided into two halves and centrifuged. The combined supernatant 
was loaded (SN! ) (figure 5.3). The pellets were dissolved in either 2 ml PBS plus 8M 
urea (P1 + urea) or 2 ml 2% SDS in PBS (P1 + SDS). The pellets were sonicated 
again twice for 20 seconds each time and re-centrifuged. The resulting pellets (P2) 
were dissolved in lx Laemmli buffer and loaded along with the supernatants (SN2). 
This allowed some of the expressed protein to be transferred from the original pellet 
into subsequent supernatant fractions for WmrecN, but not for WmrecC (not shown). 
Therefore, only the N-terminal recombinant protein, WmrecN was isolated and used to 
inject rabbits. Sera from immunised rabbits were received and purified by binding to 
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protein G columns. Protein G binds to IgG regions to purify crude serum from 
possible unspecific proteins such as albumin, thereby improving antibody specificity. 
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Figure 5.3 Bacterially expressed Wolframin N-Terminal protein. Mini-scale protein preparations from 
a WmrecN-pQE40 positive clone under denaturing conditions. Expected size of protein is 35 kDa. 
Supernatant and Pellet fractions are described in the text. 
After this, the group of Dr. Sabine Hofmann decided to tackle this solubility problem 
by fusing Wolframin to the maltose binding protein, using the pMal-C2x vector (New 
England Biolabs). This system utilises the Ptac promoter and translation initiation 
signals of the maltose binding protein (MBP) to express large amounts of protein. 
MBP has been shown to enhance the solubility of protein expressed in E. coli (Kapust 
and Waugh 1999). Another advantage of the MBP is its ability to bind amylose and 
elute with low concentrations of maltose, excluding the need for harsh detergents. In 
, .. 
._ .ý . ýý 
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this way, it was possible to successfully express both N- and C-terminal proteins and 
use these for immunisation of rabbits. 
5.2 Production of peptides as antigens for immunisation 
While recombinant proteins were being prepared, various peptide antibodies were 
chosen, conjugated to the Keyhole Limpet Hemocyanin (KLH) carrier protein and 
used to immunise rabbits. Since peptides are so small, they need to be coupled via 
glutaraldehyde with the immunologically rather unreactive KLH in order to produce an 
immune response. A Chou-Fasman prediction plot was used to determine the best 
regions to select for making peptide antibodies to the C- and N- terminal ends (figure 
5.4). 
Figure 5.4 The Chou-Fasman topological prediction plot for Wolfranun. Circles indicate hydrophilic 
regions. 
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Four N-terminal peptides were chosen, two of which were targeted to both mouse and 
human sequences and two were targeted only to mouse sequences. Two C-terminal 
peptides were made, one targeted to the human and one to the mouse sequence. Sera 
from immunised rabbits were purified on amino-link plus columns (Pierce). Amino- 
link columns contain Imidazol Carbamate, which binds the primary amines located on 
the N-terminus or lysine residues and in this way separates specific antibodies from 
antibodies that bind to unknown antigens. OD 280 nm readings were taken of the 
eluates to determine the best pools and equal amounts were loaded onto a 12% SDS 
gel to observe the quality of the resulting eluates. 
Chanter 6. Characterisation of antibodies 
6.1 Characterisation of antibodies on western blot 
A list of all antibodies and their antigens is summarised in table 6.1. All antibodies 
tested positive for reactivity against their respective antigen by using ELISA (data not 
shown). It had recently been shown by Takeda et al. that the Wolframin protein is 
very weakly expressed in Cos-7 cells and a large difference can be seen between 
transfected and non-transfected cells. Therefore, as a test to determine which 
antibodies were specific and which were not, western blot analyses were performed 
comparing untransfected Cos-7 cells and those transfected with the Wolframin 
expression construct. This analysis is shown in figure 6.1. Only two antibodies 
showed specific immunoreactivity on the western blot. These were WoN; the antibody 
against the N-terminal recombinant protein fused with MBP and h86; an antibody to 
the human C-terminal peptide. However, h86 only reacted weakly on western blots 
and did not improve when purification was repeated once more with AminoLink and 
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then with SulfoLink affinity chromatography. SulfoLink columns contain lodoacetyl, 
which binds to the suithydryl groups located on cystein residues. In this case, 
lodoacetyl was able to bind to the internal cystein located on the h86 peptide sequence. 
Interestingly, the h86 antibody was able to immunoprecipitate the Wolframin protein 
specifically from native pancreatic tissue extracts. For example, when protein 
homogenate was precipitated with h86, a strong signal at 100 kDa for Wolframin was 
seen using WoN on western blot analysis. However, when h86 was used to detect an 
h86 precipitated Wolframin protein, no signal was seen. This indicates that h86 
recognises the Wolframin protein, but shows only weak reactivity on western blot. 
Antibody Antigen Region Western IF 
Reactivity Reactivity 
m84 N-terminal as 30 - 49 - weak 
tide 
m85 N-terminal as 61 - 79 - - 
peptide 
m83 N-terminal as 187 - 206 - - 
tide 
m82 N-terminal as 203 - 222 - weak 
peptide 
m86 C-terminal as 745 - 764 - - 
tide 
h86 C-terminal as 745 - 764 weak - 
peptide 
WmrecN N-terminal as 1- 295 - - 
recombinant 
WmrecC C-terminal as 625 - 890 n. a. n. a. 
recombinant 
WoN N-terminal as 39 - 288 strong strong 
recombinant 
Table 6.1 List of antibodies used for immunisation. IF = Immunofluoresconce, n. a. = not analysed. 
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Figure 6.1. Western blot analysis of Wolframin antibodies on total protein extracts from either 
transfected or non-transfected cos-7 cells. 50µg total cell homogenate was loaded. WoN and h86 
recognize the Wolframin protein as a band of 100 kDa, which is more intense in protein from cos-7 cells 
transfected with Wolframin cDNA. 
The antibody to recombinant N-terminal protein fused with 6xHis tag, WmrecN, 
produced a strong band at the expected size, however, this band was present in equal 
concentration in untransfected cells and those transfected with Wolframin, indicating 
unspecific binding. This antibody produced a 100 kDa band in all fractions, including 
both soluble and insoluble cell extracts and non-membrane fractions (data not shown). 
m82 and m83 showed no transfection specific reactivity in the range of the expected 
size of 100 kDa and m84, m85 and m86 showed only weak, if any transfection specific 
activity. This can be seen in figure 6.1. Based on this information, the antibody WoN 
was used for all future western analyses. 
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Thus far, two antibodies have been found which recognise the Wolframin protein, an 
antibody against the N-terminal recombinant protein and an antibody against the C- 
terminal peptide. However, antibodies that did not show reactivity on western blot 
were not ruled out for their possible recognition of the Wolframin protein in other 
applications and were further characterised by immunohistochemistry on pancreatic 
slices. 
6.2 Immunohistological characterisation of antibodies 
Since Wolframin mRNA is highly expressed in pancreatic islet cells (Inoue, Tanizawa 
et al. 1998), this tissue was used as an initial control for studying the 
immunohistological reactivity of these antibodies. In addition, it is not understood 
what causes the loss of pancreatic ß-cells in Wolfram patients. Therefore, it was 
important to determine whether the ß-cell loss is a direct defect originating in the cells 
themselves or caused by a secondary effect from a-cells, pancreatic polypeptide (PP) 
or delta cell impairment. Pancreatic slices from control mice were treated with 
antibody and detected using a secondary goat anti-rabbit conjugated to FTTC- 
fluorescent dye. Immunofluorescence studies of all the antibodies made revealed four 
antibodies which showed a staining pattern different to the preserum: three antibodies 
against the N-terminal region; WoN, m82 and m84 and one against the C-terminal 
region, h86 (figure 6.2). 
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Figure 6.2 Immunofluorescence studies of all antisera produced on pancreas slices. 
/P refers to 
preserum. WoN, m82, m84 and h86 are the only antisera, which showed a 
difference to preserum. 
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WoN, m82 and m84 all showed the same pattern, although the signal from WoN was 
the most intense. h86 showed a strong signal that was different from the other three. 
In order to check the specificity of this staining, pancreas slices were stained with anti- 
insulin antibody as a control for 0-cells and with and-glucagon antibody for a-cells. 
These antibodies were detected using anti-guinea pig and anti-mouse TRITC- 
conjugated secondary antibodies for insulin and glucagon respectively. Superimposing 
images from the exact location showed that the signal from antibodies WoN, m82 and 
m84 over-lapped with insulin and not with glucagon. h86 showed an a-cell similar 
structure, but did not co-localise to glucagon (figure 6.3). Localisation to the 
polypeptide product or delta cells was not tested using the h86 antibody. Thus, WoN, 
m82 and m84 localised to the ß-cells of the pancreas. However, the signal for WoN 
was much stronger than for m82 or m84 and the expression for m82 was stronger than 
for m84. The expression of Woiframin in 0-ce11s indicates that the diabetes mellitus in 
Wolfram patients is likely due to a direct defect in ß-cell functioning. Here again, 
WoN was the antibody with the strongest immune reactivity and was subsequently 
used for sub-cellular localisation studies and all other antibody requiring analyses. 
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Figure 6.3 Immunofluorescence studies of Wolframin in pancreatic ß-cells. Control mouse pancreata 
were detected with both Wolframin specific antibodies (FITC-conjugated secondary antibody) and 
either anti-glucagon or anti-insulin (TRITC-conjugated secondary). 
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6.3 Localisation to the limbic system of the brain 
The neurological complications found in DIDMOAD patients are due to generalized 
brain atrophy (Barrett, Bundey et al. 1995). For example, the optic atrophy is caused 
by degeneration of the nerves leading to the eye. Therefore, it is probable that the 
protein is expressed in areas responsible for the various neurological symptoms. To 
observe localisation in the brain, 5µm thick sagittal slices from a mouse brain were 
incubated with the WoN antibody at a dilution of 1: 500 and detected using a secondary 
goat anti-rabbit conjugated to FITC (figure 6.4). 
Figure 6.4 Immunofluorescence studies of the expression of Wolframin in sagittal mouse brain slices. 
Strong signal can be seen in the CAI region pyramidal cells of Ammon's horn in the hippocampus (A) 
and in the purkinje cells of the cerebellar cortex (B). 
Localisation in the brain was found in the CAI region of the pyramidal cells of the 
Ammon's horn in the hippocampus. Strong expression was seen in the ependymal 
layer and in individual brain nerve nuclei and neuronal groups from the forebrain. 
Purkinje cells of the cerebellar cortex were the only cells stained in this area. The 
hippocampus and cerebellar cortex both belong to the limbic system and are 
responsible for emotion, behaviour, anxiety and/or panic including depression. These 
findings suggest a function for the Wolframin protein in the control of emotion and 
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behaviour and are in accordance with the fact that WS patients and even heterozygous 
individuals are susceptible to psychiatric illness (Swift, Polymeropoulos et al. 1998). 
Therefore, destruction of the Wolframin protein could lead to abnormal psychiatric 
functioning in these patients by directly disturbing interactions in the limbic system of 
the brain. 
Chapter 7. Test of WoN on various tissues, cell lines and fibroblast cells from 
controls and our patients 
After discovering that Wolframin protein expression was found in the ß-cells of the 
pancreas, expression of isolated islet cells and exocrine tissue from control mouse 
pancreas was investigated on western blot (figure 7.1). 
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Figure 7.1 Expression of Wolframin in Pancreas homogenate and endocrine and exocrine fractions. 
High expression can be seen in the endocrine fraction as compared to pancreas homogenate and the 
exocrine fraction. Normalisation of band intensities was done using the AIDA program. 
Pancreas Exocrine Endocrine 
Pancreas Exocrine Endocrine 
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Dr. Schremmer-Danninger (Institute for Diabetes Research) provided the endocrine 
and exocrine fractions for this analysis. A much higher expression level in endocrine 
pancreas than in exocrine pancreas was seen. However, it was surprising that there 
was expression at all in exocrine fractions. It could be possible that the exocrine 
fractions are slightly contaminated with endocrine tissue. 
The cell lines tested were two ß-cells lines: OTC-tet and R7TI and an a-cell line: In- 
R1-G9 (figure 7.2). 
In-R1-G9 ßTCtet R7T1 
MAM. - IV, 
.- WoN 
ß-actin 
Figure 7.2 Expression of Wolframin in cell lines. 50 ug of total protein homogenates from either In- 
R1-G9, OTC-tet or R7TI cell lines were loaded onto a 10% SDS-PAGE gel and detected with WoN. A 
very weak band could be seen with longer exposures in the lane 1. 
OTC-tet cells come from a non-clonal cell line derived from a male mouse insulinoma 
of transgenic background expressing the SV40T antigen oncoprotein in pancreatic ß- 
cells under control of the bacterial tetracycline repressor/operator system (Efrat, Fusco- 
DeMane et al. 1995). These cells use the tet-off approach, in which cells proliferate in 
the absence of tet ligands and undergo growth arrest in their presence. R7T1, on the 
other hand, utilises the tet-on regulatory system, in which cells divide in the presence 
of ligands and undergo growth arrest in their absence. This cell line is derived from 
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insulinomas from transgenic mice treated with the tetracycline derivative, doxycycline 
(dox) (Milo-Landesman, Surana et al. 2001). The R7T1 cell line is advantageous for 
in vivo experiments and transplantation because no ligand is needed for long-term 
maintenance of growth arrest in vivo. The a-cell cell line, In-R1-G9, comes from the 
hamster insulinoma cell line, In-111-R1, and produces glucagon (Takaki, Ono et al. 
1986). This analysis revealed high expression in islet cells and both ß-cell lines and a 
low expression in the a-cell line. 
4 WoN 
Figure 7.3 Expression of Wolframin in fibroblast cells from WS patients and control individuals. 50µg 
total protein homogenate was loaded from PatEC, Control, Sib13 and Pat14. 
Moderate expression was seen in fibroblast cells from healthy individuals and Sib13 
(figure 7.3). Pat14 showed a slightly lower level of expression as Sib13, indicating 
that protein is produced in this patient. Since this patient contains a nonsense mutation 
leading to an early truncation on one allele and a missense mutation on the other allele, 
production of the full-length protein is possible. These mutations on both alleles could 
cause the phenotype seen in this patient by not allowing the protein to appropriately 
interact or complete its normal functions. This analysis does not give any insight into 
how much function is retained in the produced protein. It is possible, for example, that 
PatEC Control Sib13 Pat14 
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this protein cannot be properly folded or is not able to react with other proteins as it 
otherwise would. PatEC showed no band at 100 kDa, as was expected from the 
mutational analysis. This patient contains an insert resulting in a severely truncated 
protein on both alleles and should not be able to produce the full-length protein. In 
addition, the N-terminal specific antibody, WoN, did not detect a lower molecular 
weight band that could result from the truncated protein. Therefore, the truncated 
version of the Wolframin protein in PatEC is most likely not stable enough for 
detection. 
Chanter 8. Sub-cellular localisation 
8.1 Analysis of sub-cellular fractions on western blot 
As mentioned in the introduction, the Wolframin gene contains no signal sequence 
recognition sites to give an indication of sub-cellular localisation. PSORT is a 
computer program which utilises amino acid sequences to determine where such 
proteins will most likely localise (Nakai and Horton 1999). The amino acid sequence 
encoded by Wolframin predicts an integral transmembrane protein with 65% 
probability for localisation to the plasma membrane, 26% to the endoplasmic reticulum 
and 4% to the mitochondria. The symptoms seen in the Wolfram syndrome are similar 
to many known mitochondrial disorders, as discussed in the introduction. It was 
therefore hypothesised that despite the structure predictions, this protein could localise 
to the mitochondria. Determining the sub-cellular localisation of a novel protein is 
essential to ascertaining its function and provides a starting point for further analysis. 
In order to check this, both western blot and immunofluorescence techniques were 
used. Mouse brain was used to extract cell fractions for western blot analysis. Nuclear 
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(N), mitochondrial (Mit), microsomal (Mic) and cytosolic (Cyt) fractions were 
collected (figure 8.1). Anti-protein disulfide isomerase (a-PDI) was used as an ER 
marker and anti-translocon inner membrane protein complex 23 ((x-Tim23) as a 
mitochondrial marker to check these fractions for purity. PDI sits on the lumen of the 
ER and is involved in protein folding. Calnexin, an ER membrane localised protein 
was also used to check individual fractions, however, this protein has approximately 
the same molecular weight as the Wolframin protein and could be not used for double 
staining. Calnexin showed ER staining in the same fractions as PDI (data not shown). 
Tim23 is a mitochondrial protein complex, which mediates the translocation of 
proteins into the mitochondrial matrix and is located on the inner membrane of the 
mitochondria. Surprisingly, Wolframin co-localised exclusively to the ER-containing 
microsomal fraction and not to the mitochondria as was previously suspected based on 
the disease phenotype. 
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Figure 8.1 Localisation of the Wolframin protein in cell fraction extracts. Whole mouse brains were 
homogenised and fractionated into nuclear (Nuc), mitochondrial (Mit), microsomal (Mic) and cytostolic 
(Cyt) fractions. 50µg of each protein was loaded and detected using either anti-WoN (1: 200), anti- 
TIM23 (1: 500) or anti-PDI (1: 1000). The WoN antibody recognised a 100 kDa band for the Wolframin 
protein in the ER enriched fraction. 
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8.2 Sub- cellular localisation on cell lines 
Fibroblasts, which were shown in figure 7.3 to express the Wolframin protein, were 
tested for immunofluorescence studies. Cells were grown overnight on chamber slides 
and incubated on the next day with various antibodies and again detected with FITC or 
TRITC conjugated secondary antibodies depending on the host animal of the primary 
antibody. In contrast to immunohistochemical studies on tissue slices, the expression 
in fibroblast cells from control individuals was too weak to see a significant signal 
(figure 8.2). There was hardly a difference between preserum and WoN. Myoblast 
cells (obtained from Dr. Sabine Hofmann), which showed a slightly higher protein 
expression on western blots as fibroblasts also showed no distinct difference between 
preserum and WoN. Therefore, immunofluorescence was tested with OTC-tet cells, 
since they show a very high expression on western blot. These cells showed a definite 
difference between preserum and WoN and the intracellular distribution appeared to be 
very similar to that of a-PDI. However, due to their size and the fact that they grow in 
clumps, even in a differentiated state, distinct intracellular structure could not be 
properly observed (figure 8.2). Finally, Cos-7 cells were transfected with Wolframin 
using pIRES vector under regulation of the CMV promoter with Lipofectamine 
(Gibco). This showed a much stronger signal, which differed greatly in its structure 
from preserum (figure 8.2). In order to determine its localisation, antibodies to the ER 
(anti-PDI), mitochondria (Mitotracker red) and golgi (anti-58k protein) were observed 
on transfected Cos-7 (figure 8.3). The WoN staining pattern was very similar to cells 
stained with ER antibodies and not similar to golgi or mitochondrial structures. WoN 
was then co-localised with anti-PDI, Mitotracker Red and anti-58k (figure 8.4). 
Superimposing the green images of WoN with the red images of organelle-specific 
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antibodies showed virtually identical overlap with PDI and only partial overlap with 
anti-58k, as indicated by the yellow colour. 
Human Fibroblasts 
Human Myoblast Cells 
ITCtet Cells 
'f ransfected Cos-7 
Figure 8.2 Expression of Wolframin in various cell lines. Cells were incubated with either rabbit 
preserum (1: 50) or anti-WoN (1: 50) serum decorated with FITC conjugated anti-rabbit second antibody. 
anti-WW'oN Serum I) F( I imi 
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Figure 8.3 Immunofluorescence of various antibodies on Cos-7 cells transfected with the Wolframin 
cDNA. 
Figure 8.4 Co-localization of Wolframin in transfected Cos-7 cells. Cos-7 cells were transfected 
withWolframin cDNA vector and incubated with WoN antibody (1: 50) (A, D, G). The same cells were 
incubated with either (B) anti-PDI for the ER, (E) anti-Golgi 58k for the Golgi or (H) mitotracker for 
the mitochondria. Overlaying these signals (C, F and I) shows overlap between the green WoN and the 
red anti-PDI (ER), a slight overlap can be seen with the red anti-Golgi 58k and no overlap is seen with 
the red mitotracker. 
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Chanter 9. Functional analysis of Wolfram syndrome patient cells 
9.1 Microarray 
After determining that Wolframin is expressed in fibroblast cells, it was decided to use 
these cells or cell extracts for various functional tests. An attempt was made to 
determine what other genes could possibly be affected by a malfunction in the 
Wolframin gene. Such information was desirable as a starting point for further 
functional analyses since at this point no data was known about the function of this 
protein. The effects of the Wolframin gene defect on the expression of other genes 
was analysed using Microarray chip technology. Microarray is advantageous in that it 
can quantitatively analyse expression levels of many thousands of genes in parallel. 
This method can identify genes involved in many diseases and developmental 
processes. For this purpose, poly A+ RNA was isolated and 600 ng at 50 ng/141 was 
sent to Incyte Genomics for analysis. Poly A+ RNA from Sib 13 was labelled in a 
reverse transcription reaction with Cye3-dUTP and Pat14 labelled with Cye5-dUTP. 
These samples were used to probe the human UniGEMV2.0 microarray chip, which at 
this point contained approximately 10,000 genes per analysis. Comparing first-grade 
relatives lowers the possibility of differences due to altered genetic backgrounds. The 
expression pattern of most genes did not differ significantly from one another. Only 
very few genes appeared to be differentially expressed by a factor of 1.8 or more. 
Table 9.1 shows a list of the genes with the largest differences between siblings. 
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Genes with lower expression in Pat14 cells 
-3.8 ectonucleotide pyrophosphatase/phosphodiesterase 
(PC- plasma cell membrane glycoprotein) 
-2.5 lioma pathogenesis-related protein (RtP) 
-2.0 desmoplakin PI, DP 
-2.0 microtubule-associated protein IB 
-1.9 Homo sapiens cDNA FLJ 11245 fis, clone 
-1.9 HIV-1 reverse binding protein 2 
Genes with higher expression in Patl4 cells 
2.1 EGF-containing fibulin-like extracellular matrix 
protein 1 Fibulin 3) 
2.0 ferritin, heavy polypeptide 1 
2.0 zinc finger protein 238 
1.9 collagen, typ e VIII, alpha 1 
1.8 cysteine-rich pro tein 1 (intestinal) 
1.8 microsemino in, beta 
Table 9.1 List of genes found to up and down regulated after microarray analysis comparing poly A+ 
RNA from fibroblast cells from Pat14 and Sib13. 
Interesting to note is the 3.8 times down regulated expression of the human plasma 
membrane glycoprotein, PC-1. PC-1 is an ecto-nucleotide pyrophosphatase/ 
phosphodiesterase, which most likely plays a role in the control of extracellular 
pyrophosphate, insulin signalling and in the calcification of bone and cartilage 
(Okawa, Nakamura et al. 1998; Johnson, Vaingankar et al. 1999). Knocking out the 
PC-1 gene in mice causes calcification in and around joints and ligaments. This gene 
inhibits the insulin receptor signalling pathway by acting directly on the a-subunit of 
the insulin receptor (IR) (Maddux and Goldfine 2000). In cells, including skin 
fibroblasts from insulin resistant Type 2 diabetics, as well as in those from non-obese, 
insulin resistant, non-diabetic subjects, the phosphatase expression is significantly 
higher (Maldux, Sbraccia et al. 1995). This is exactly opposite in fibroblast cells from 
WS patients. In these fibroblast cells, PC-1 mRNA expression is lower than in control 
persons. This is not too surprising, since the diabetes in DIDMOAD patients is not 
based on insulin resistance as in Type 2 diabetes, but is due to a selective loss of ß- 
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cells. It appears however interesting, that a gene which is over-expressed in Type 2 
diabetics is down regulated in DIDMOAD patient cells. 
Of the genes up regulated in DIDMOAD fibroblasts, EFEMPI (epidermal growth 
factor-containing fibrillin-like extracellular matrix protein 1 or fibulin 3) was the most 
interesting. EFEMPI is a widely expressed extracellular matrix protein of unknown 
function. It has been shown to be over-expressed in senescence cells from Werner 
patients and can be induced by serum-deprivation of young cells (Lecka-Czernik, 
Lumpkin et al. 1995). The fact that EFEMPI is over-expressed in cells from both 
Wolframin and Werner patients led to a later experiment testing our cells for their 
sensitivity to y- radiation and apoptotic induction. In addition, a single mutation, 
R345W, in the EFEMPI gene causes the disease, Malattia Levantinase (ML) or Doyne 
honeycomb retinal dystrophy (Katsanis, Venable et al. 2000). This is an autosomal 
dominant disease characterised by the build-up of drusen (sub-retinal pigment 
epithelium deposits), geographical atrophy, decreased visual acuity and blindness. 
These drusen accumulations are due to misfolding of the mutated EFEMPI protein 
(Marmorstein, Munier et al. 2002). Considering the fact that optical atrophy is a 
requirement for WS, it might be possible that a defect in Wolframin could indirectly 
cause changes in EFEMPI that in turn cause optical atrophy and blindness. 
EFEMPI protein expression clearly shows a stronger signal in Pat14 fibroblast cell 
homogenate than in Sib13, as can be seen in figure 9.1. This protein expression 
difference is in accordance with microarray results. 
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Figure 9.1 Western analysis of the EFEMPI antibody on fibroblast cell extracts from Pat14 and Sibl3. 
EFEMPI showed a stronger expression in Pat14 cells then in Sib13 cells. 
9.2 Susceptibility to X-ray radiation 
According to Microarray analysis, EFEMP1 is over-expressed in fibroblasts lacking 
functional Wolframin. An over-expression of EFEMPI has also been reported for 
senescent cells and cells from Werner Syndrome patients (Lecka-Czernik, Lumpkin et 
al. 1995). Therefore, two senescence markers, growth rate and sensitivity to radiation, 
were compared between cells from Patl4 and Sibl3 (figure 9.2). 10.000 cells were 
plated per well of 24-well dishes. Two hours following plating, the cells were 
irradiated with either 1 Gray or 5 Gray using a Co-Gamma source (9,76 Gray/min) or 
mock treated. At the times indicated, all cells of a single 24 well were thoroughly 
trypsinised and the total cell number (not discriminating potentially dead or apoptotic 
cells) were determined by Coulter counting (Coulter Electronics/Beckmann). During 
the time-course examined, non-irradiated control cells were not reaching cell numbers 
that lead to density inhibition, as was evident from the respective growth curves. As 
seen in figure 9.2, both treated and untreated cells showed no significant differences 
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with regard to their genotypes. Therefore, under these conditions, it could not be 
proven that Wolframin deficient cells are more susceptible to radiation. 
Figure 9.2 Radiation sensitivity test to determine if fibroblast cells from Wolfram syndrome patients 
are more susceptible to senescence. -0 =0 Gray, -1 =1 Gray and -5 =5 Gray used for radiation. 
9.3 Apoptosis 
The atrophy of selective neurons in the brain and the loss of ß-cells in the pancreas in 
WS patients gave an indication that these cells or tissues are more sensitive to 
apoptosis. For this reason, it was hypothesised that fibroblast cells from our patients 
could be more susceptible to induced cell death. Therefore, a staurosporine induced 
apoptosis assay was used to examine the difference between healthy and diseased cells 
(figure 9.3). 
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Caspase-3 Activity in Fibroblast Cells 
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Figure 9.3 Specific activity of caspase-3 in Sibl3 and Pat 14 fibroblast cells. Fibroblast cells were 
induced for apoptosis with staurosporine alone or staurosporine and apoptosis inhibitor for 6 hours and 
specific activity calculated. Pat14 is 3.8 times more susceptible to staurosporine-induced apoptosis than 
Sibl3. 
Staurosporin inhibits protein kinase C (PKC) by interaction with the catalytic domain 
close to the ATP-binding site (Nakano, Kobayashi et al. 1987). Pat14 and Sib13 cells 
were seeded onto 6-Well plates, grown overnight and staurosporine was subsequently 
added at a concentration of 0.5µM for 6 hours. The cells were then trypsinised and 
lysed in cell lysis buffer from the CaspACE assay system, colorimetric kit (Promega). 
The activity of caspase-3 was measured after induction for apoptosis with 
staurosporine, a common induction route for programmed cell death. Caspase-3 is a 
member of the cysteine aspartic acid specific protease family involved early on in the 
apoptotic process as a main effector caspase. It cleaves on the aspartate residue of the 
sequence Asp-Glu-Val-Asp (DEVD) (Gurtu, Kain et al. 1997). In this assay, the 
substrate, Ac-DEVD-pNa is added to equal concentrations of protein lysate on a 96- 
Well plate. p-Nitroaniline (pNa) is a chromophore, which produces a yellow colour 
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after caspase-3 has cleaved Ac-DEVD-pNa and released free pNa. This colour can be 
read at 405 nm and samples compared with one another. Calculation of the specific 
activity of caspase-3, taking into consideration natural cell death by inhibition with the 
caspase inhibitor, Z-VAD-FMK, was recorded as pmol pNa liberated per hour per µg 
protein. This revealed 3.8 times more caspase-3 activity for Pat14 as for Sib13. 
Therefore, Wolframin patient fibroblast cells are more susceptible to stauroporine- 
induced apoptosis. 
9.4 Glycosylation 
The Wolfranvn gene product is an N-glycosylated ER membrane protein. It could be 
possible that the symptoms in DIDMOAD are due to a defect of glycosylation. For 
example, features of congenital disorders of glycosylation (CDG) include atrophy and 
polyneuropathy (Freeze 2001). Therefore, general glycosylation patterns in Woiframin 
deficient fibroblast cells were tested. For this experiment, serum from PatEC and one 
parent were obtained. Transferrin glycosylation is a commonly used marker for such 
disruption. The transferrin receptor is highly expressed in all non-eurythroid cells. In 
fact, on the surface of proliferating cells, 10,000 to 100,000 molecules per cell are 
expressed (Chitambar, Massey et al. 1983; Gatter, Brown et al. 1983), thereby making 
this a good indicator of general glycosylation. Improper glycosylation of the 
transferrin receptor confers inability to bind transferrin, which results in an inability to 
deliver iron to tissues. Normal human transferrin can be found in several isoforms 
depending on differences in glycosylation (de Jong and van Eijk 1988). These 
transferrin isoforms can be characterized by the number of sialic acid residues present 
(de Jong, van Dijk et al. 1990). Dr. Klaus Gempel (Institute for Clinical Chemistry, 
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Munich, Germany) performed capillary electrophoresis analysis to determine the levels 
of transferrin isoforms. 
However, as can be seen in figure 9.4, the various transferrin glycosylation levels are 
the same in patient and control sera. Therefore, the defects seen in DIDMOAD are 
most likely not due to improper glycosylation. 
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Figure 9.4 Capillary electrophoresis experiment to determine transferrin glycosylation in PatEC and a 
parent of PatEC. No difference was seen in levels of transferrin isoforms between these two samples. 
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Chanter 10. Wolframin knock-out mouse 
DIDMOAD is a very rare disease and material to study is difficult to obtain. In 
addition, not all WS patients contain mutations resulting in a complete loss of 
functional protein. For these reasons, a knock-out mouse construct was planned. 
Sequence analysis has shown no yeast homologue and no known natural mutant mice 
have been found to exist. Strom et al. (1999) showed that the mouse homologue of 
Wolframin is 83% identical to the human variant. Therefore, in order to investigate 
the ramification of a complete loss-of-function of the Wolframin gene in various 
tissues, a knock-out mouse model was planned that would render the last exon, exon 8, 
non-functional. In addition, there is no phenotypic difference between patients 
containing homozygous mutations leading to a truncated protein and less severe 
mutations. This exon was chosen because it encodes 72% of the entire gene, covers all 
transmembrane regions and a majority of mutations are found in this region. Initially, 
no information was known about the genomic sequence of Wolframin, therefore, a 
mouse 129/OLA cosmid library from the Resource Center of the German Human 
Genome Project (RZPD, Berlin, Germany) was searched to determine which pools 
contained Wolframin genomic sequences. Primary and secondary PCR pools were 
screened for positive clones. Only one positive clone was found in this search and the 
clone was requested. Unfortunately, this clone was a false positive as it contained 
sequences from the Wolf-Hirschorn Syndrome, interestingly also located on 
Chromosome 4p16 and the Wolframin gene was not present. In a second attempt, 
genomic DNA was sequenced using the GenomeWalker kit from Clontech. Using this 
method, a3 kb fragment was produced as the 5' arm for homologue recombination in 
this knock-out mouse construct. A 1.1 kb long 3' fragment from the end of exon 8 was 
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amplified and both fragments were cloned into the pBluescript H cloning vector. In 
order to interrupt exon 8 and render the resulting protein inactive, the neomycin gene 
was inserted between the 5' and 3' arms on the pBluescript II clone. The neomycin 
gene was also used as a positive selection marker to allow selection of homologue 
recombination events with Genticin (G418). This construct was linearised and 
electroporated into the embryonic stem cell line, R1-ES. I performed all R1-ES cell 
techniques at the Max Planck Institute for molecular neurobiology in Heidelberg, 
Germany in the laboratory of Dr. Rolf Sprengel. 600 colonies were picked, plated onto 
96-well plates and PCR screened in pools of 6 with a nested PCR using two reverse 
primers that anneal to the target chromosomal sequences just outside of the homology 
used in the vector and two forward primers from the 3' end of the neomycin insert. 
Unfortunately, no positive knock-out clones were found with PCR screening. Since 
the 5' region used in our construct was relatively short and this could have lead to a 
lower probability of homologue recombination, this region was chosen as a target for 
improving the construct. Luckily, the full genomic sequence became available to the 
public in this time. This information was used to produce a Wolframin knock-out 
mouse construct consisting of a 5.3 kb long 5' fragment and a 3' fragment 1.1 kb long 
(figure 10.1). 
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Figure 10.1 Wolframin knock-out mouse construct. The 5` homologous region is 5.3 kb long and 
contains sequences spanning from intron 3 to intron 7, the neomycin positive selection vector was 
inserted into the region spanning from intron 7 to the beginning of exon 8, thereby excluding 1.9 kb of 
seqnences and rendering exon 8 inactive. The regions of homologue recombination are indicated by 
X's. The closed circle indicates position of the southern probe. 
A neomycin selection vector was placed in the exon 8 coding region to disrupt this 
exon and result in a non-functional protein. In addition, 1.9 kb of Wolframin sequence 
were excluded by amplifying the 3' and 5' segments around this area. This construct 
was also linearised and electroporated into R1-ES cells. From this analysis, two 
positive pools were found and propagated from 96-wells into 24-wells and the 
individual pools screened again by PCR. At this stage, two individual clones were 
found and propagated to several 10 cm dishes. Genomic DNA was isolated and the 
clones checked by southern blot analysis. The DNA was cut with Sac! and a 3' probe 
was used to determine the size difference in knock-out DNA and genomic DNA. The 
sequences for a Sac 1 site were present in the section that was excluded in the knock- 
out construct. Therefore, digestion with Sac l should have resulted in 2082 bp 
fragment for wild-type and 4103 kb for the transgenic allele. As can be seen in figure 
10.2, only the band for wild-type was present. Thus, neither of these clones proved to 
be correct. At the moment, a new knock-out mouse construct is being produced, 
which includes 7 kb of sequences for the 5' homologue recombination and 1.4 for the 
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3' region. The 3' region is also being changed and new primers selected for PCR 
screening to allow positive clones to be found. 
+º 4w < 2082 kb 
Figure 10.2 Southern blot of PCR positive Wolframin mouse knock-out clones. DNA was cut with 
SacI and probed with a 3' end PCR product. The wt allele should result in a 2082 bp band and the 
knock-out allele in a 4103 bp band. Both clones produced only the band representative of the wt allele. 
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Chanter 11. Discussion 
Wolframin was discovered in 1998 by two unrelated groups to be the gene responsible 
for the Wolfram Syndrome. Both groups found loss-of-function mutations on two 
alleles in a majority of patients tested. Wolframin was a novel gene and its encoded 
product was completely uncharacterised at the start of this thesis. Using the amino 
acid sequences, a transmembrane protein was predicted that showed no resemblance to 
any other known protein. The Wolframin sequence contained no information as to its 
possible localisation or function. 
In order to gain insight into the possible function of this gene, its expression during the 
development of cyclophosphamide enhanced diabetes in NOD mice was examined. 
The expression changes in brain and pancreas detected during the course of diabetes 
induction gave the first indications that the Wolframin protein could play a direct role 
in the tissues affected in WS patients. In contrast, the auto-immune mediated type 1 
diabetes mellitus is a result of at least 18 genes contributing to an immune response 
(Davies and Day 1994). 
The next step was then to determine if the protein itself was expressed in the ß-cells of 
the pancreas. In order to investigate this, antibodies were raised against various C- and 
N- terminal peptides and recombinant proteins. One antibody, WoN, showed proper 
expression on western blot and immunohistological analysis. Indeed, it was shown 
that the Wolframin protein is expressed in insulin-producing ß-cells. Since WS 
patients show a selective loss of ß-cells and the Wolframin protein is expressed in 
these cells, it is possible that the Wolframin gene product plays a role in the survival of 
ß-cells. 
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Exactly what functions or interactions are important for the Wolframin protein could 
be better understood by determining its sub-cellular localisation. A 100 kDa band, 
which was the expected size based on amino acid sequences for the Wolframin protein 
was seen in western analysis of purified microsomal fractions. No band was seen in 
the nuclear, mitochondrial or cytosolic fraction. 
Unfortunately, the cell types tested for immunofluorescence studies were not adequate 
to determine the endogenous expression. Either expression was too low or cells were 
not large enough to observe structural patterns. Therefore, Cos-7 cells were first 
transfected with a Wolframin expression construct and used for immunofluorescent 
detection. This showed a pattern similar to the ER specific antibody, PDI. Co- 
localisation of these two antibodies proved that the Wolframin protein does reside in 
the endoplasmic reticulum. OTC-tet cells also showed an over-lapping staining pattern 
for WoN and PDI, however, these cells were too small to observe proper intracellular 
structure. This was a surprising result, as the symptoms seen in DIDMOAD are 
similar to many mitochondrial related diseases. Localisation to the plasma membrane 
was ruled out by Takeda et al. (2001) by showing that the plasma membrane enriched 
fraction was negative for Wolframin. Microsomal fractions have been tested for N- 
glycosylation and Endo H sensitivity (Takeda, Inoue et al. 2001) and by others at the 
Institute for Diabetes Research (unpublished data). In both cases, a shift in band size 
was seen. This is additional evidence that the Wolframin protein does localise 
properly to the ER. Thus, the Wolframin protein is an Endo H sensitive type 2 
(cytoplasmic amino terminus) integral membrane glycoprotein of unknown function. 
It has been previously reported that ß-cells have a highly developed ER needed for 
insulin secretion (Oyadomari, Araki et al. 2002). Disturbing proper functioning of the 
ER results in cellular damage and eventually apoptosis. The ER is an organelle 
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responsible for the processing, trafficking, proper folding of newly synthesised 
proteins and regulation of calcium stores. When any of these functions are disturbed, 
the ER finds itself in a stage of "ER stress". As a self-protective mechanisms against 
ER stress, cells undergo what is called the ER stress response (Kaufman 1999). 
Prolonged periods of ER stress lead to apoptotic cell death by several different 
pathways (Oyadomari, Araki et al. 2002). In fact, it has been reported that ß-cells, the 
first cells affected in the WS, are among the most susceptible cells to ER stress 
mediated apoptosis (Oyadomari, Koizumi et al. 2002). 
The Wolcott-Rallison syndrome, as described in the introduction, is due to mutations 
found in the ER-localised EIF2AK3 gene. EIF2AK encodes for pancreatic ER kinase 
(PERK) (Delepine, Nicolino et al. 2000). PERK attenuates translation initiation in 
response to ER stress, thereby protecting ß-cells from ER stress (Harding and Ron 
2002). PERK deficient mice develop hyperglycaemia at four weeks of age and show 
increased apoptosis in ß-cells (Harding, Zeng et al. 2001). The Wolcott-Rallison 
syndrome is an example of a diabetic phenotype resulting from mutations in an ER- 
localised ß-cell residing protein. In this case, the ability to respond to ER stress is 
important for the survival of ß-cells. 
This thesis provides evidence that the Wolframin protein is also localised to the ER 
and ß-cells of the pancreas. The Wolframin gene product has some sequence 
similarity to SEL-1 and Hrd3p, from Caenorhabditis elegans and yeast respectively. 
These proteins play an important role in degrading malfolded ER proteins. If 
Wolframin also had a role in degrading malfolded ER proteins, then Wolframin 
defective cells should show a difference to non-defective cells undergoing ER stress. 
Indeed, fibroblast cells from a Wolfram patient showed a 3.8 fold higher increase in 
caspase-3 activity than a non-affected sibling after induction for apoptosis with 
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staurosporine. The next step in determining Wolframin's possible function in ER 
stress response will be to induce these fibroblast cells with more ER stress-specific 
inducers. In addition, caspase-12, a recently identified caspase, responds specifically 
to ER stress to activate downstream caspases to induce apoptosis (Rao, Hernlel et al. 
2001). It would be interesting to observe the levels of caspase-12 in addition to 
caspase-3. If Wolframin is indeed involved in the ER stress response, than it could be 
possible that its own protein expression increases in states of ER stress. Such an 
experiment could also be done on pancreatic ß-cells, which would be advantageous, 
since the diabetic phenotype suggests more activity in ß-cells. 
It is also possible that the Wolframin protein functions as a channel or as a mediator by 
interacting with other proteins. At least the last 8 residues are important for the 
function of the entire protein (Barrett, Bundey et al. 1995). The importance of these 
residues could feasibly lie in their protein-protein interaction with yet unknown 
partners. The PERK protein, for example, has its stress-sensing domain in the ER 
lumen, where it interacts with the binding protein, BiP (Bertolotti, Zhang et al. 2000; 
Liu, Schroder et al. 2000). When proteins accumulate in the ER luman, BiP detaches 
and allows PERK to become active. Maybe the last 8 residues of Wolframin, which 
also lie in the lumen, are important for activation in ER stress. When the ER stress 
response does not function properly, an increase in apoptosis could occur. Interactions 
of this protein with others is currently being investigated here at the Institute for 
Diabetes Research and should prove to be valuable information for determining a more 
precise function of this protein. 
In another attempt to gain functional data about the Wolframin gene, a microarray 
analysis was performed with mRNA isolated from fibroblast cells from a WS patient, 
Patl4, and a sibling, Sibl3. This analysis resulted in two interesting genes; PC-1 and 
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EFEMPI. The PC-1 gene was down regulated in DIDMOAD patient fibroblast cells 
and is an ecto-nucleotide pyrophosphatase/phosphodiesterase of unknown function. It 
is interesting to note that members of the phophodiesteraselnucleotide pyrophsphatase 
(PDNP) family play a role in neuromodulation in CNS and PNS, renal function and 
nociception (pain awareness) (Burnstock 1995; Buell, Collo et al. 1996; Thorn and 
Jarvis 1996). Considering the neurological and endocrine symptoms associated with 
WS, the significance of the down-regulation of PC-1 may be in its interaction with 
these neurological functions. It would be interesting to know to what degree, PC-1 
plays a role in these functions. For example, comparing PC-1 staining patterns in the 
brain to those of Wolframin would give an indication of their possible interaction. 
This will have to be investigated in future experiments. 
EFEMPI is a widely expressed extracellular matrix protein of unknown function and 
was up regulated in DIDMOAD patient fibroblast cells. This gene has been shown to 
be over-expressed in Werner patients and can be induced by serum deprivation 
(Katsanis, Venable et al. 2000). Werner patient cells and serum deprived cells are both 
senescent. An attempt to determine if Wolframin plays a role in senescence by 
ascertaining its susceptibility to radiation proved negative. A single mutation in 
EFEMPI causes build-up of misfolded EFEMPI protein resulting in the Malattia 
Levantinase (ML) disease. Normally, the EFEMPI protein is found in the nerve fiber 
layer (NFL) and the photoreceptor inner and outer segments in the eye (Marmorstein, 
Munier et al. 2002). In ML patient eyes, the retinal pigment epithelium is strongly 
stained with EFEMPI antibody. Abnormal protein accumulation can be due to defects 
in either: protein folding, transport or degradation, all of which involve ER membrane 
proteins. Defective protein processing is a cause of several neurodegnerative diseases. 
For example, abnormal processing of the ER membrane amyloid precursor protein is 
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responsible for Alzheimer's disease and results in vulnerability to apoptosis (Haass, 
Grunberg et al. 1998). In order to understand the relationship of the Wolframin 
protein in the eye, histological staining patterns in the retina for Wolframin protein 
need to be investigated. Observation of the expression of EFEMPI in retina from 
Wolframin negative mice would also provide valuable information. 
The expressed genes found in this microarray analysis did not differ greatly from one 
another. A more prominent difference may have been better observed between normal 
OTC-tet cells and OTC-tet containing a disrupted Wolframin protein because the 
patient phenotype suggests that Wolframin plays a large role in endocrine tissue. 
Disrupting the Wolframin gene can be achieved for example using antisense technique. 
The best comparison would have been the difference between heterozygous and 
homozygous Wolframin knock-out mice. However, the production of these mice 
could not be completed during the course of this work. 
After determining that the Wolframin protein is expressed in the ß-cells of the 
pancreas, the expression pattern in the mouse brain was investigated. These findings 
corresponded with findings from Takeda et al. 2001, who also discovered expression 
in areas of the limbic system of the rat brain. This expression pattern is interesting 
since a majority of WS patients develop psychiatric and emotional abnormalities, 
including depression. Strom et al. (1998) have also reported that even individuals 
harbouring mutations on only a single allele are at a 26-fold higher risk of developing 
affective disorder. Expression of the Wolframin protein in these areas suggests a 
possible role for Wolframin in control of emotion and motivation. Lower expression 
was found in the cerebellum compared to other areas, although MRI from patients has 
revealed major atrophy of this area. However, it is not essential for protein expression 
to correlate exactly with affected areas. It could very well be that effects of the 
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malfunctioning protein lead to ER stress, which causes apoptosis in other areas of the 
brain. Wolframin might also be important for the activation of other proteins that have 
functions in other areas. These aspects need to be further investigated. 
Many of the results obtained from these experiments lead to further ideas, which could 
be tested in knock-out mice. Two attempts have already been made to produce a 
knock-out mouse without success. In the last mouse construct, 5.3 kb of sequences 
were made available for homologue recombination, however no positive clones were 
obtained. It appears that the Wolfranmin locus only very inefficiently undergoes 
homologue recombination. It may be that 5.3 kb of homology are not enough. It has 
been reported that the relationship between targeting frequency and the length of 
homology in a replacement vector are found to increase linearly (Hasty, Rivera-Perez 
et al. 1991). Therefore, in another attempt to produce a knock-out mouse, a new 
construct is being designed containing over 7 kb of homology at the 5' end and 1.4 kb 
at the 3' end. The region at the 3' end is also being changed so that the PCR analysis 
hopefully will not result in false positives as encountered before. Should this new 
construct result in a Wolframin knock-out mouse, it will be a valuable tool for 
understanding the Wolframin gene and gene product. 
This thesis presents data, which give the first indication towards characterisation of the 
Wolframin gene. It encodes for a transmembrane protein that resides in the ER 
membrane and localises to all tissue homogenates tested thus far and more specifically 
to the ß-cells of the pancreas and structures of the limbic system of the brain. 
Fibroblast cells from DIDMOAD patients are more susceptible to caspase-3 activation 
after induction for apoptosis. Therefore, increased susceptibility to apoptosis in 
neurons and cells of the endocrine system may be involved in the pathogenesis of the 
Wolfram syndrome. However, the exact function of this gene still needs to be 
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investigated. Understanding the molecular mechanisms underlying the Wolframin 
gene is important for understanding the relationship of neurodegeneration and diabetes 
mellitus in Wolfram syndrome patients. 
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